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Résumé 
 
L’émergence de l’utilisation du méthylphénidate (MPH; Ritalin) par des 
étudiants universitaires afin d’améliorer leur concentration et leurs 
performances universitaires suscite l’intérêt du public et soulève d’importants 
débats éthiques auprès des spécialistes. Les différentes perspectives sur 
l’amélioration des performances cognitives représentent une dimension 
importante des défis sociaux et éthiques autour d’un tel phénomène et méritent 
d’être élucidées. Ce mémoire vise à examiner les discours présents dans les 
reportages internationaux de presse populaire, les discours  en bioéthique et en 
en santé publique sur le thème de l’utilisation non médicale du 
méthylphénidate. Cette recherche a permis d’identifier et d’analyser des 
« lacunes » dans les perspectives éthiques, sociales et scientifiques de 
l’utilisation non médicale du méthylphénidate pour accroître la performance 
cognitive d’individus en santé. 
Une analyse systématique du contenu des discours sur l’utilisation non 
médicale du méthylphénidate pour accroître la performance cognitive a identifié 
des paradigmes divergents employés pour décrire l’utilisation non médicale du 
méthylphénidate et discuter ses conséquences éthiques. Les paradigmes  « choix 
de mode de vie »,  « abus de médicament » et « amélioration de la cognition » 
sont présents dans les discours de la presse populaire, de la bioéthique et de la 
santé publique respectivement. Parmi les principales différences entre ces 
paradigmes, on retrouve : la description de l’utilisation non médicale d’agents 
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neuropharmacologiques pour l’amélioration des performances, les risques et 
bénéfices qui y sont associés, la discussion d’enjeux éthiques et sociaux et des 
stratégies de prévention et les défis associés à l’augmentation de la prévalence 
de ce phénomène. 
La divergence de ces paradigmes reflète le pluralisme des perceptions 
de l’utilisation non médicale d’agents neuropharmacologiques Nos résultats 
suggèrent la nécessité de débats autour de l’amélioration neuropharmacologique 
afin de poursuivre l’identification des enjeux et de développer des approches de 
santé publique cohérentes. 
Mots clefs: Neuroéthique, amélioration des performances, utilisation non 
médicale d’agents neuropharmaceutiques, méthylphénidate, 
représentations publiques 
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Abstract 
The non-medical use of neuropharmaceuticals has sparked ethical 
debates. For example, there is mounting evidence that methylphenidate (MPH; 
Ritalin) is being used by healthy university students to improve concentration, 
alertness, and academic performance, a phenomenon known as cognitive 
enhancement. The different perspectives on the ethics of cognitive enhancement 
represent an important dimension of the social and ethical challenges related to 
such practices but have yet to be examined thoroughly. This thesis aimed to 
assess existing positive and negative reports in international print media, 
bioethics literature, and public health literature on the use of MPH to identify 
and analyze gaps in the ethical, social, and scientific perspectives about the non-
medical use of MPH for cognitive enhancement in healthy individuals.  
A systematic content analysis of discourses on the non-medical use of 
methylphenidate for cognitive enhancement identified divergent frameworks 
employed to describe the non-medical use of methylphenidate and discuss its 
ethical implications: The frameworks of “lifestyle choice”, “prescription drug 
abuse” and “cognitive enhancement” are present in print media, bioethics, and 
public health discourses respectively. Important differences between 
frameworks include the description of the non-medical use of 
neuropharmaceuticals for cognitive enhancement, associated risks and benefits, 
discussion of ethical and social issues surrounding the phenomenon and the 
prevention strategies and challenges to the widespread use of 
vi 
  
neuropharmaceuticals for cognitive enhancement.  
Diverging frameworks reflect pluralism in perceptions if the non-
medical use of neuropharmaceuticals for cognitive enhancement. At this time, 
unacknowledged pluralism and implicit assumptions about cognitive 
enhancement may impede public health interventions and ethics discussions.  
Keywords: Neuroethics, cognitive enhancement, non-medical use of 
prescription drugs, methylphenidate, public understanding 
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The non-medical use of neuropharmaceuticals is generating substantial 
debates in academic, medical and public health circles. A key motive for this 
non-medical use of neuropharmaceuticals is the enhancement of cognitive 
function in healthy individuals beyond normal human capacity. There is 
substantial evidence that methylphenidate, a drug typically prescribed to 
manage the symptoms of Attention Deficit/Hyperactivity Disorder (AD/HD) in 
children and adults, is being used by healthy university students to improve 
concentration, alertness, and academic performance. The ethics and public 
understanding represents an important dimension of the social and ethical 
challenges related to such practices and merit close scrutiny.  
The research presented in this thesis aims to tackle some of the ethical 
issues related to cognitive enhancement by examining systematically discourses 
on this phenomenon. In particular, it analyzes existing positive and negative 
reports in the international print media, bioethics discourse and public health 
discourse on the misuse of methylphenidate. Underlying this project is the 
belief that close attention to current discourses could allow for the identification 
and analysis of divergences to enrich discourses. It is important to identify and 
analyze such gaps to move forward in the analysis of the ethical, social, and 
scientific perspectives about the non-medical use of methylphenidate for 
cognitive enhancement in healthy individuals.  
Chapter 1 consists of a review of the literature on cognitive 
enhancement. The chapter first tackles the different definitional approaches to 
the non-medical use of neuropharmaceuticals for cognitive enhancement in 
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healthy individuals. The non-medical use of methylphenidate in university 
students for enhancement of academic performance illustrates a context for 
examining closer the ethics of cognitive enhancement. Chapter 1 proceeds with 
a cursory overview of the most prominent ethical and social issues surrounding 
the non-medical use of neuropharmaceuticals. Finally, the literature review 
examines the public understanding of neurotechnology as one of the major 
issues in the non-medical use of neuropharmaceuticals.  
The methodological approaches used to carry out the research described 
in this thesis are the subject of Chapter 2.  This chapter describes the 
methodology used to identify the relevant discourses (print media, bioethics 
literature and public health literature) on the non-medical use of 
methylphenidate for cognitive enhancement. The chapter on methodology also 
elaborates upon the systematic coding that lead to the identification and 
analysis of divergences in discourses on ethical, social and scientific issues 
surrounding the non-medical use of methylphenidate for cognitive 
enhancement.  
The results of our research on the ethics and public understanding are 
presented in three sections. Chapter 3 is an article entitled “A second look at the 
ethics of cognitive enhancement” that was published in April 2007 in Canadian 
Psychiatry Aujourd’hui. This short article reviews the prevalence rates of the 
non-medical use of neuropharmaceuticals for cognitive enhancement of healthy 
individuals and introduces some of the ethical issues that arise for this 
phenomenon, in particular given the existence of diverging paradigms. This 
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chapter concludes by considering the potential impact of ethical issues upon 
future policy on cognitive enhancement and calls for broader social discussion.  
Some of the first results of the analysis of discourses on the non-medical 
use of methylphenidate for the cognitive enhancement of healthy individuals 
are presented in Chapter 4. This brief communication entitled “Cognitive 
enhancement, lifestyle choice or misuse of Prescription Drugs? Ethics blind 
spots in current debates”. The three paradigms used to approach cognitive 
enhancement in different discourses on the phenomenon are described in detail. 
In addition, the publication identifies some important “ethics blind spots” which 
may complicate broader social discussion of cognitive enhancement. 
Our complete discourse analysis on the non-medical use of 
methylphenidate for cognitive enhancement is the subject of the manuscript in 
Chapter 5. Entitled “Potential implications of determining discourses on the 
ethics of non-medical use of methylphenidate for performance enhancement” 
this article describes additional components of the different paradigms 
presented in Chapter 4 and explains why they diverge. The content examined in 
each discourse include the description of the nature of the non-medical use of 
methylphenidate for cognitive enhancement in healthy individuals, associated 
risks and benefits, ethical and social issues as well as prevention strategies and 
challenges to wider spread non-medical use of neuropharmaceuticals for 
cognitive enhancement. The paper concludes that disagreements between the 
paradigms could have important healthcare, ethics and social implications and 
consequences. As a result, they call for bioethics and the print media to 
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reinvigorate their commitment to public information and informed debate while 
medicine, healthcare and society prepare for potential broader non-medical use 
of neuropharmaceuticals for performance enhancement. 
In light of the diversity in discourses on the non-medical use of 
neuropharmaceuticals for the cognitive enhancement of healthy individuals 
Chapter 6 expands upon the discussion of Chapter 5 to outline additional 
potential implications of diverging perspectives on cognitive enhancement. The 
general discussion begins by evoking some antecedents in the lifestyle use of 
psychopharmacology and their importance for future discussions about 
cognitive enhancement. Lessons for cognitive enhancement from the history of 
psychopharmacology include awareness of the importance of social context in 
the non-medical use of neuropharmaceuticals, adequate research into efficacy 
and safety of potential cognitive enhancers in healthy individuals and 
management of commercial interests. The discussion continues with the 
beginnings of a framework for a potential role for public health in the current 
context of enthusiasm for the non-medical use of neuropharmaceuticals. 
Finally, the discussion concludes by proposing engagement of the public in 
debates on the non-medical use of neuropharmaceuticals by healthy people. 
Based on our research we believe that the ethical issues related to the 
non-medical use of neuropharmaceuticals for the cognitive enhancement of 
healthy individuals will be inescapable. It will be important for various 
stakeholders to engage in future debates, especially that this phenomenon 
becomes more prevalent.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Background on the ethics and public understanding of cognitive 
enhancement with methylphenidate 
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The non-medical use of prescription drugs to enhance performance is a 
phenomenon growing in prevalence and raising ethical concerns. This chapter 
aims to examine the ethics and public understanding of the non-medical use of 
methylphenidate for cognitive enhancement in four parts.  First, the different 
definitional approaches and terms used in discussing enhancement will be 
considered. Second, the chapter will introduce the non-medical use of 
methylphenidate as a context for studying the broader phenomenon of cognitive 
enhancement. Third, the ethical and social issues of cognitive enhancement will 
be discussed. Finally, public understanding will be evoked as an important 
ethical and social matter regarding cognitive enhancement. The chapter 
provides background information on the nature and ethics of non-medical use 
of methylphenidate for cognitive enhancement.  
Definitional approaches 
Semantic pluralism surrounds the non-medical use of 
neuropharmaceuticals in healthy individuals to increase performance. The 
bioethics literature has coined several terms to refer to cognitive enhancement 
such as “neurocognitive enhancement” [51], “neuroenhancement” [62], 
“cosmetic psychopharmacology” [72], and “cosmetic neurology” [35]. Due to 
the nature of prescription drugs, in the public health literature, we find terms 
like “illicit use of prescription medication” [84], “prescription abuse” [85] and 
“non-medical use of prescriptions” [82]. The medical literature has also used 
the term “lifestyle use” of prescription drugs [53]. In reporting on cognitive 
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enhancement, the print media has developed popular vocabulary reflected by 
phrases like “better living through chemistry” [163] and a “new kind of drug 
abuse” [75]. Some of these terms are potentially synonymous; however others 
carry with them subtle implications. The term “non-medical use” will often be 
used in this thesis because of its relative neutrality in reference to uses of 
pharmaceuticals for performance enhancement. The choice of this term is also 
meant to encompass features of three common definitional approaches i.e., 
“enhancement”, “prescription drug abuse” and “lifestyle use of prescription 
drugs”. We speak here of “definitional approaches” rather than definitions 
because current definitions carry theoretical assumptions notably about how the 
non-medical use of neuropharmaceuticals relates to healthcare. 
Enhancement 
The improvement of cognition can be associated with medicine in 
different ways therefore, before proceeding, it is important to delineate what the 
term “cognitive enhancement” can mean. A general definition of cognitive 
enhancement is the “amplification or extension of core capacities of the mind 
through improvement or augmentation of internal or external information 
processing systems” [124]. Collectively, these processing systems are known as 
“cognition” which is a “combination of skills, including attention, learning, 
memory, language, praxis (skilled motor behaviors), and so-called executive 
functions, such as decision making, goal setting, planning, and judgment” 
[153]. Cognitive function can be improved by both pharmacology and medical 
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devices [88]. Thus, in its purest state, cognitive enhancement simply signifies 
the improvement of cognitive function. However, improving cognition can have 
different goals and occur in different contexts. First, cognition can be improved 
as a medical goal which is the case of the treatment of Alzheimer’s disease. For 
example, donepezil (Aricept) is given to older adults to improve long-term and 
short-term memory as well as working memory and recognition tasks [161]. 
Second, improving cognition can be considered an enhancement when the 
cognitive function of a healthy individual is modified with the goal of 
improving performance on a certain task [51]. Such improvements of cognition 
can inhabit the blurry region between what is considered to be a medical 
treatment and what is considered an enhancement [159]. This thesis will refer to 
cognitive enhancement essentially in the second context, i.e., to reflect the goal 
of performance enhancement in healthy individuals beyond “average” or 
“normal” capacity. 
The dichotomy between treatment and enhancement exacerbates 
confusion about the appropriate terms to use in reference to the non-medical use 
of psychopharmacology performance enhancement. Often, the terms 
“treatment” and “enhancement” are used in opposition.  As part of this 
distinction, an enhancement is “designed to produce improvements in human 
form or function that do not respond to legitimate medical needs” [68]. 
Consequently, this approach ousts improvements in the healthy from the 
boundaries of healthcare.  According to this perspective, an enhancement can 
be defined as what is not medically necessary. By opposing the two terms, 
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medical necessity may be perceived as a uniquely scientific parameter. 
However, Wolpe suggests that, “what we consider disease intervention and 
what we do not (…) will conform to what the culture, or medical professionals, 
see as the proper objects of medical intervention” [159]. Accordingly, it may be 
more useful and somewhat clearer to consider treatment and enhancement as 
two poles on a continuum instead of mutually exclusive terms [68]. This more 
fluid perspective on the relationship between treatment and enhancement has 
yet to fully penetrate the writings of most ethicists who still consider that the 
two terms are difficult to distinguish in the case of performance enhancement 
but rely heavily on them to articulate their thinking [25, 35, 86].  Although this 
is often implied, no data exists to our knowledge showing that healthcare 
professionals and the public have such difficulty distinguishing treatment from 
enhancement in practical settings. This does not imply that scholars are wrong 
but that perhaps broader lenses would be needed. 
Drawing a clear moral line between treatment and enhancement 
represents a monumental challenge given the different ethical and philosophical 
perspectives involved [107] but the distinction is still significant at many levels 
[159].  For reasons of medical insurance and reimbursement the healthcare 
system must have a clear definition of what constitutes a medical necessity.  
Sabin and Daniels have proposed models for equitable distribution of resources 
within a population based on “normal functioning” [120] and a “species-typical 
functioning” [43]. The goals of these models are to equally and justly distribute 
medical resources for medical needs such that enhancements are not covered by 
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the healthcare system. Inclusion or exclusion of improving performance in 
healthy individuals from healthcare could impact the responsibility of 
healthcare professionals. Healthcare professionals are often regarded as the 
“gatekeepers” to technologies with enhancement properties thus changes in the 
treatment-enhancement distinction could also modify the way these 
technologies are dispensed [35]. Lastly, a distinction is useful from an ethical 
standpoint to determine whether medicine, the law, public policy and ultimately 
society deem performance enhancement as beneficial for citizens [30, 100, 
105]. While it may be easier to consider the treatment and enhancement as a 
spectrum as opposed to a clear distinction, there is interest in clarifying where 
improving the performance of healthy individuals lies for systemic, 
professional, and ethical reasons. 
Prescription drug abuse 
The use of prescription pharmaceuticals for reasons other than those 
medically intended represents a potentially growing health problem in Canada 
and the United States (US). In the wake of an increase in the abuse of 
neuropharmaceuticals Health Canada has defined “prescription drug abuse” as: 
use of pharmaceutical drugs with centrally acting reinforcing 
properties that is associated with increased risk for harm, as 
characterized by obtaining drugs from illegitimate sources, or 
risky patterns of use (excluding under-use), that deviate from 
accepted medical practice and/or scientific knowledge, or taking 
the drugs for purposes which are non-therapeutic [28]. 
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Prescription drug abuse has been the focus of much scrutiny in recent years. As 
of 2005, 48 million Americans over the age of 12 admitted to using a 
prescription drug for a non-medical reason in their lifetime [94]. The classes of 
drugs abused varies but there is evidence that drugs that alter brain function like 
opioids (painkillers), central nervous stimulants (amphetamines) and 
depressants (antidepressants) are among the most abused [28, 94]. A report 
From the US National Survey on Drug Use and Health found that between 2002 
and 2005, an annual average of 11.4 million individuals reported non-medical 
use of pain medication alone in the year prior to the survey [98]. This report 
also indicated that past year non-medical use of prescription pain medication 
was highest among young adults aged eighteen to twenty-five.  
There are only few if any Canadian statistics on the prevalence of 
prescription abuse but some feel that there is still cause for concern given 
Canada’s prevalent use of prescription drugs. In recent years, Canada has 
ranked fourth internationally for use of sedative-hypnotics and was among the 
top fifteen countries for the use of prescription stimulants [28, 64]. Studies have 
also identified patterns of adolescent and university student stimulant abuse in 
Canadian institutions [15, 103, 104]. The abuse of prescription stimulants is by 
no means restricted to Canada. It seems to be an emerging phenomenon on 
university campuses across North America as well as some other professional 
settings [5, 154]. 
Increased prevalence of the non-medical use of prescription drugs is a 
potential public health concern given its effects on the healthcare system.  Non-
13 
  
medical uses of prescription drugs have been associated with increased visits to 
the emergency room. An estimated 1.4 million visits to US emergency rooms 
are linked to prescription drug abuse [85]. One study positively correlated 
increases in the number of prescriptions for opiates with an increased number 
of drug-induced and drug-related emergency room visits in the US [157]. This 
data suggests that the use of prescription drugs for reasons unrelated to the 
health of an individual could strain healthcare systems. However some fear that 
prevalence of the non-medical use of prescription medication may not only be 
due to increased availability of these drugs but rather a lack of access to good 
healthcare [52]. As a result, certain types of conditions may be under-diagnosed 
potentially leading individuals to self-medicate which is thought to indicate that 
the non-medical use of prescription drugs is not inherently abusive or non-
medical. 
Distribution of controlled substances also represents a potential public 
health concern with regard to the non-medical use of prescription drugs. There 
is evidence that prescription medication is being diverted into illicit markets 
[60, 64]. Many studies have shown that prescription stimulants represent a class 
of drug that is often diverted [83, 84, 104, 155]. There are suspicions that wider 
availability of prescription drugs is contributing to increased prevalence of their 
non-medical use [157] but no definite link has been made to date.  Other 
potential contributing factors to the spread of the non-medical use of 
prescription drugs include the low cost of prescription drugs relative to illegal 
drugs [85] and the emergence of Internet pharmacies [94]. There are reports 
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that prescription stimulants are being obtained on black markets [16, 75, 92, 
101] as well as over the Internet [16, 97, 101, 119] for non-medical use with the 
goal of cognitive enhancement.  The diversion of prescription drugs, especially 
those with properties favoring performance enhancement contribute to the 
perception that the non-medical use of psychopharmaceuticals for cognitive 
enhancement lies outside of healthcare. 
Lifestyle use of prescription pharmaceuticals 
 The lifestyle use of pharmaceuticals is related to the non-medical use of 
pharmaceuticals for cognitive enhancement in its goal but differs from 
prescription drug abuse in its relation to medicine. A lifestyle drug is one “used 
for non-health problems or for conditions that lie at the boundary between a 
health need and a lifestyle wish” [55] and is administered by a healthcare 
professional. Examples of such conditions are social phobia, baldness and 
erectile dysfunction [77]. However, another view has been presented. Lifestyle 
drugs can also be used to treat “lifestyle illnesses” which are “diseases arising 
from lifestyle choices” [77]. Flower’s review of lifestyle drugs, their primary 
clinical uses as well as their lifestyle uses [53] was based upon an editorial by 
Young outlining the four different types of lifestyle drug [162]. The first type is 
a class of drugs that is approved specifically for lifestyle use. For example, 
orlistat (Xenical) whose primary clinical use is in obesity is also used as 
lifestyle drug to promote weight loss in non-obese individuals. The second 
category is formed of drugs that have been approved for one indication but 
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produce other effects which can satisfy a lifestyle purpose sometimes 
qualifying as an off-label use. An example of such a drug is minoxidil 
(Rogaine) that can control hypertension but also re-grow hair. The third and 
fourth classes of drugs, illegal drugs and natural products, fall slightly outside 
the scope of this thesis as they are not prescription pharmaceuticals. 
Nonetheless, the examples in Flower’s table illustrate the niche occupied by 
lifestyle drugs somewhere between treatment and enhancement. 
Lifestyle drugs represent a lucrative market. Since 1990, twenty billion 
dollars have been invested in the research and development of lifestyle drugs. 
In 2002 the lifestyle drug market was estimated to be worth twenty billion 
dollars and was projected to grow to twenty-nine billion by 2007 [10]. The 
market for lifestyle drugs has gained significant importance over the last decade 
such that it has been suggested that the demand for lifestyle drugs may drive 
physicians into being “lifestyle consultants” [35]. However not all are 
convinced arguing that physicians and citizens may not let medical ethics be so 
easily overpowered by market pressures [44]. Whatever the changes come in 
the healthcare system as a result of the increased use of lifestyle drugs, they will 
have to tackle some important questions, notably the treatment-enhancement 
distinction. 
Lifestyle drugs are generally viewed as a part of healthcare. Though the 
use if these drugs may border on enhancement they are still recognized as 
treatment. However, the treatment status of something like orlistat (Xenical) to 
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promote weight loss begs the question of whether lifestyle drugs are “turning 
natural expressions of human behavior into a ‘disease’ that requires- or would 
benefit from- drug treatment” [53]. This way, a lifestyle wish (e.g., being thin) 
is transformed into a medical necessity, a process often called “medicalization” 
[40, 55, 80]. On the contrary some also believe that medicalization has 
improved health over the years [51]. For example, the development of oral 
contraceptives, drugs that to not cure but prevent, has positively impacted 
family planning. Despite the positive impact, one concern looms in the light of 
medicalizing some aspect of human behavior. It is feared that lifestyle drugs, 
especially for the treatment of so-called lifestyle illnesses “remove[s] 
responsibility or control from the individual or society” [55]. Consequently, 
medicalization of human behavior may soften the consequences of a lifestyle 
choice like smoking because nicotine addiction can be controlled by medication 
and does not represent the health hazard it once did. A change in attitude 
toward lifestyle drugs has the potential to impact the ways healthcare providers 
use pharmacology. Lexchin maintains that it is not the role of a healthcare 
provider to deal with social injustices by prescribing drugs [77]. Continued use 
of lifestyle drugs is likely to call for the rethinking of medical necessity, public 
health policies, resource allocation and society’s role in the concept of health 
[55, 80]. 
The cursory overview of the terms “enhancement”, “prescription drug 
abuse” and “lifestyle use of prescription drugs” has illustrated how the subject 
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of cognitive enhancement spans the treatment-enhancement spectrum. It 
remains unclear which of these terms, if any, are most appropriate to describe 
the non-medical use of psychopharmaceuticals for cognitive enhancement 
seeing since each carries subtle implications. For example, the term 
“enhancement” implies that the effects elicited from the drugs in question are 
beneficial, that they will necessarily improve something. On the other hand, this 
term is also more goal-oriented and seen as the antithesis of a treatment. This 
also implies that enhancement is often viewed as unnecessary as we noted. The 
term “prescription drug abuse” carries a negative connotation inviting 
comparisons with the abuse of illicit (illegal) drugs which does not always 
intend to improve performance. Like “enhancement”, “prescription drug abuse” 
situates the non-medical use of a neuropharmaceutical for performance 
enhancement outside medicine. The “lifestyle use of prescription drugs” reflects 
in part the goal of improving performance but requires a medical diagnosis of 
some kind of deficiency. Because of its reference to some kind of “normal” or 
“average” state, the lifestyle use of prescription drugs could involve the 
medicalization of some facets of human behavior. A first step in simplifying the 
vocabulary has been made by Merkel et al. who proposed a framework for 
determining proper use, misuse and abuse of psychopharmaceuticals [88]. Their 
assessment of the proper use of stimulants is relative to the presence/absence of 
symptoms in the context of Attention Deficit/Hyperactivity Disorder. They 
claim that the goal of enhancing performance corresponds to a “non-therapeutic 
use” of a stimulant which is similar to the term “non-medical use” (non-medical 
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is broader because the use of some pharmaceuticals medically are more 
complex than simple treatment) employed in this thesis. However, the authors 
do not indicate how one might procure a stimulant for a non-therapeutic use or 
whether it may be acceptable to do so. While the constellation of terms used in 
reference to the non-medical use of neuropharmaceuticals hinders semantic 
continuity, the multiple terms reflect a complex relationship between the goal 
of improving performance and the proper use of medical interventions as well 
as the complexity of this topic in a pluralistic society.  
The non-medical use of methylphenidate for cognitive enhancement 
Cognitive enhancement  
The emergence of the cognitive enhancement of healthy individuals has 
been gradual. The phenomenon is generally associated with uses of prescription 
drugs that are not officially indicated called “off-label” uses. Table 1-1 lists 
some examples of drugs that were developed for the treatment of medical 
conditions but have been used for cognitive enhancement.  In 2002, Yesavage 
et al. conducted a study where middle-aged licensed aircraft pilots were given 
donepezil, a cholinesterase inhibitor used in the treatment of Alzheimer’s 
disease [161]. By monitoring the pilots’ performance on a flight simulator, the 
investigators found that the pilots were able to better retain information when 
given the drug. Modafinil regulates sleep/wake cycles in patients suffering from 
conditions like narcolepsy and sleep apnea. However, 90% of prescriptions for 
modafinil are for off-label purposes, for example to increase alertness in people 
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suffering from jetlag [146]. Drugs seemingly unrelated to cognitive have also 
proven to elicit some kinds of enhancement. For example, Pitman et al. 
conducted experiments where propranolol, a blocker of the beta-androgenic 
receptor which helps to control hypertension, alleviated the severity of post-
traumatic stress disorder (PTSD) [102].  
Table 1-1: Primary medical uses and cognitive enhancement uses of some 
prescription neuropharmaceuticals 
Medication Primary medical use Cognitive enhancement use 
donepezil 
(Aricept) Alzheimer’s disease 
Increase ability to retain 
information 
modafinil 
(Provigil) 
Narcolepsy/sleep 
apnea Remedy jetlag 
propanolol 
(Inderal) 
Cardiovascular 
disease Prevent post-traumatic stress 
 
There may be ethical issues associated with the uses of these medications in the 
context of the illnesses they are intended to treat. However, performance 
enhancement is distinct from “off-label” uses by physicians because 
performance enhancement uses are neither medically prescribed nor supervised.  
As a result, use of cognitive enhancers in healthy individuals raises many 
ethical issues that will be discussed at length in the remainder of this chapter 
using the specific example of the non-medical use of methylphenidate, one of 
the most salient contemporary examples of cognitive enhancement. 
20 
  
Cognitive enhancement using methylphenidate 
Perhaps the most compelling example of the non-medical use of 
psychopharmaceuticals for cognitive enhancement is the use of 
methylphenidate (Ritalin) by healthy students who do not suffer from Attention 
deficit/hyperactivity disorder (AD/HD). Recent studies have reported that this 
form of performance enhancement is a widespread reality affecting North 
American university campuses [5, 154]. Students are reportedly obtaining 
methylphenidate both illicitly (from friends and colleagues, black markets, 
Internet pharmacies) and licitly (feigning symptoms of AD/HD to obtain 
prescriptions) to improve attention, concentration and alertness in order to 
enhance their academic performance. Similar patterns of prescription use have 
recently been reported in a Nature-sponsored survey where 20% (N=288/1427) 
of respondents used drugs non-medically to improve concentration, focus and 
memory [79]. This phenomenon has received moderate attention from the print 
media but is being closely examined in bioethics and public health. Table 1-2 
provides an overview of most of the studies examining the non-medical use of 
prescription stimulants in adolescent and university populations. Studies 
reporting the use of prescriptions stimulants specifically for enhancement 
purposes are identified in another table in Chapter 4.  Table 1-2 also reflects the 
language used in each study to describe the use of the stimulants. 
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Table 1-2: Overview of public health studies on the prevalence of the non-medical use of prescription stimulants  
Author Year Journal Sample population Study design Prevalence 
Babcock & 
Byrne[11] 2000 
Journal of American 
College Health 
283 students in a public 
liberal arts college 
Self-report mail 
survey 
16.6% 
(recreational use of 
methylphenidate) 
Poulin[103] 2001 Canadian Medical Association Journal 
13 549 students in 
grades 7, 9, 10 and 12 
Self-report 
anonymous 
questionnaire 
8.5% 
(non-medical stimulant use) 
Low & 
Gendaszek[58] 2002 
Psychology, Health & 
Medicine 
150 undergraduates at a 
small college in the US 
Self-report 
questionnaire 
35.3% 
(illicit use of prescription 
amphetamines) 
 
Teter et al.[140] 2003 Pharmacotherapy 
Random sample of 
2250 undergraduate 
college students 
Self-report web 
survey 
3%                          
(past year illicit methylphenidate 
use) 
Hall et al. [61] 2005 Journal of American College Health 381 undergraduates 
Self-report 
questionnaire via 
web and writing 
13.7%                        
(illicit use of prescription 
stimulants)  
McCabe et al. [82] 2005 Addiction 
10 904 college students 
from 119 4-year 
colleges in the US. 
Self-report mail 
survey 
6.9% (lifetime); 4.1% (past-
year); 2.1% ( past month)        
(non-medical prescription 
stimulant use) 
Teter et al.[141] 2005 Journal of American College Health 
 9 161 undergraduate 
students 
Self-report web-
based survey 
8.1%  (lifetime); 5.4% (past-
year) (illicit use of prescriptions 
stimulants) 
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Prudhomme White 
[152] 2006 
Journal of American 
College Health 
1 025 random sample 
at a medium-sized 
university in New 
Hampshire 
Self-report 
Internet survey 
16%                                (abusing 
or misuse of prescription 
stimulants)  
Teter et al.[142] 2006 Pharmacotherapy 4580 college students Self-reported web-based survey 
8.3% (lifetime); 5.9% (past-year) 
(Illicit use of prescription 
stimulants) 
Novak et al.[96] 2007 
Substance Abuse 
Treatment, 
Prevention, and Policy
4 297 adults 18 to 49 
years old 
Compiled 
national survey 
results 
2%                                       (past 
year non-medical use of 
prescription ADHD 
medications) 
DeSantis et al. 
[45] 2008 
Journal of American 
College Health 
1 811 undergraduates 
at a large US university
Self-report survey 
and interviews 
34% 
(illegal use of prescription 
ADHD medications) 
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Variability in the design of pubic health studies on the prevalence of the 
non-medical use of stimulants makes it difficult to assess the extent of the 
phenomenon. The studies in Table 1-2 show that prevalence rates for the non-
medical use of prescription stimulants range from 2% [96] to 35.3% [58] in 
different American student populations and different patterns of use. This wide 
range may be due to the heterogeneous research methods used for each study. 
Samples sizes vary (e.g., random sampling vs. self-reporting) as well as the 
research tools used (e.g., questions in survey). Consequently, prevalence rates 
may be either over or underestimated. Many of the studies rely upon self-
reporting which may influence response rates. The population concerned may 
demonstrate a strong response rate which may cause over reporting or may be 
reticent to respond because of associated negative perceptions (discussed earlier 
in this chapter) thus causing under-reporting. Evidence that prevalence rates my 
not be adjusted to current practices (or vice versa) is present in McCabe et al.’s 
study on the perceptions of university students on the non-medical use of 
prescription drugs [81]. McCabe et al. found that students overestimated the 
prevalence of the phenomenon with regard to a national survey in the US on the 
same subject. More concerted efforts may be needed to come to a closer 
estimate of prevalence but this does not deter from concurrent ethics scrutiny. 
Methylphenidate 
Methylphenidate hydrochloride (Ritalin) was synthesized in 1944 in the 
laboratories of the pharmaceutical company Ciba [99] and is currently a product 
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of Novartis. It is a mild stimulant of the central nervous system acting on the 
dopaminergic system [89]. The exact mechanism of action of the stimulant has 
yet to be elucidated but it has been found to have prominent effects on attention 
and concentration as well as some effects on motor activities. Methylphenidate 
is one of the most commonly used stimulants in the management of Attention 
Deficit/Hyperactivity Disorder (AD/HD) [160] due to its capacity to improve 
attention and reduce hyperactivity. Methylphenidate is indicted for both 
children and adults.  Despite its prevalent use in children methylphenidate 
carries several contraindications and risks (Box 1-1) [29].  
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Due to its abuse potential, methylphenidate is a Schedule II substance in the 
United States [136] and a Schedule III substance in Canada [1]. These types of 
substances cannot be possessed by individuals without permission, i.e., a 
prescription.   
Debates around the use of methylphenidate have made the drug a 
familiar name in the ethics literature, medical field and the public sphere. 
Treating AD/HD with methylphenidate has evoked difficult dilemmas for 
Box 1-1: Contraindications and risks of methylphenidate based on product 
label (Novartis Canada) 
Common risks 
Insomnia 
Jitters 
Cardiac arrhythmia 
Palpitations 
Increase in blood pressure 
Stomach pain 
Vomiting 
Dizziness 
Fatigue 
Dry mouth 
Dependence 
Contraindications 
Anxiety 
Tension 
Agitation 
Hyperthyroidism 
Arteriosclerosis 
Cardiovascular disease 
Hypertension 
Glaucoma 
Pheochromocytoma (tumor of the 
sympathetic nervous system) 
Motor tics 
Tourette’s syndrome 
Hypersensitivity to drug  
Rare risks 
Stroke 
Seizure 
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parents who appreciate the effects of methylphenidate on the behavior of their 
child but fear that the medication may negatively affect their child’s 
development (e.g., slowing growth) [63, 137]. Others worry that demands upon 
children in terms of behavior and performance may be contributing to the rise 
in prevalence of AD/HD diagnosis and treatment with methylphenidate [46]. 
The treatment of AD/HD with methylphenidate has also been criticized as a 
quick fix for behavioral problems [41]. Already controversial in its medical use, 
methylphenidate continued to be a subject of interest when it was found to be a 
stimulant of choice for healthy individuals seeking to improve attention and 
concentration [11, 79, 142, 152]. Because of its use as treatment and 
enhancement, effects of methylphenidate make for a good context in which to 
study cognitive enhancement. 
Attention deficit/hyperactivity disorder (AD/HD) 
 Attention deficit/hyperactivity disorder (AD/HD) is a medical condition 
and one of the most common childhood psychiatric disorders. According to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) an estimated 3% 
to 7% of school-aged children have AD/HD with greater prevalence in boys.  
The condition is characterized by “a persistent pattern in inattention and/or 
hyperactivity-impulsivity that is more frequently displayed and more severe 
than is typically observed in individuals at comparable levels of development” 
[9]. There are three types of AD/HD which are (1) the inattentive type, (2) 
hyperactive-impulsive type and (3) combined inattentive-hyperactive type with 
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the third type being most common [54]. Some studies have suggested that 
genetic factors and differences in cerebral structures influence behavior 
however social influences are also believed to play a crucial role in the onset of 
AD/HD[9, 138]. In recent years the AD/HD diagnosis has also been extended 
to adults although it is unclear whether adult AD/HD follows the exact same 
patters as in childhood [69]. Typical treatment for AD/HD includes a 
prescription stimulant such as methylphenidate (Ritalin) or amphetamines 
(Adderall).  Behavioral therapy is often recommended to accompany 
pharmacological treatment however it is not always followed or available [41]. 
 The diagnosis of AD/HD has evolved considerably in the last century. 
Symptoms of what is now considered AD/HD are said to have first been 
described by Sir George Frederick Still [139] at the turn of the twentieth 
century. It was only in 1968 that the American Psychiatric association created 
the first set of diagnostic criteria for a condition they called “hyperkinetic 
reaction of childhood (or adolescence)” which was present in the second edition 
of the DSM [6]. At that time the diagnostic criteria were simply “overactivity, 
restlessness, distractibility, and short attention span.” In 1980 the condition was 
renamed “attention deficit disorder” [7]. While hyperactivity was recognized as 
a part of attention deficit disorder in the DSM III the revised version of 1987 
added the hyperactivity component to the condition’s name [8].  
Since 1968 the diagnostic criteria have evolved considerably. Box 1-2 
provides a brief summary of AD/HD diagnostic criteria currently being used. 
Two separate tests exist for the inattention and hyperactivity-impulsivity 
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components of AD/HD. Some examples of symptoms of inattentiveness include 
failing to give close attention to detail, having difficulty with organization and 
being easily distracted. Symptoms of hyperactivity-impulsiveness are seen in 
individuals who fidget, have difficulty engaging in quiet activities, talk 
excessively and have difficulty awaiting their turn [9]. 
 
 
 In the absence of clear biological markers for the diagnosis of AD/HD 
some effort has been made to quantify the diagnosis criteria to promote uniform 
diagnosis (e.g., minimum of six symptoms must be present in two 
environments). However, the criteria remain largely qualitative and have been 
criticized for serving “social or cultural purposes, such as bringing deviant or 
socially undesirable behavior under medical surveillance and control” [138]. 
The debate over the validity of diagnostic criteria for AD/HD is a concrete 
Box 1-2: Diagnostic criteria for Attention-Deficit/Hyperactivity Disorder in 
the Diagnostic and Statistical Manual of Mental Disorders IV-TR 
• Six or more of the symptoms of inattention or hyperactivity-
impulsivity must be present. 
• The symptoms must have persisted for at least 6 months and be 
inconsistent with normal development. 
• Some of the hyperactive-impulsive or inattentive symptoms should be 
present before 7 years of age. 
• Symptoms should be present in two or more settings (e.g., school, 
work, and home). 
• There must be evidence that the symptoms are impairing in social, 
academic or professional activities. 
• Symptoms are not concurrent with any other psychiatric condition. 
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example of the difficulty of establishing a clear treatment-enhancement 
distinction. The case of AD/HD and methylphenidate also provides an 
interesting context to study the ethical issues related to cognitive enhancement 
of healthy individuals given the prevalence of the non-medical use of AD/HD 
medications like methylphenidate.  
Ethical and social issues surrounding cognitive enhancement 
 
The previous sections of this first chapter have presented definitional 
approaches regarding the non-medical use of neuropharmaceuticals for 
cognitive enhancement illustrated with the example of methylphenidate use. 
Some types of modification of cerebral function for enhancement purposes are 
theoretically possible although evidence is scattered but whether they are 
ethical and socially acceptable is a pressing question. For several years the 
ethics of whether healthy individuals ought to enhance their cognition have 
been examined. In 2003, the US government published Beyond Therapy a 
report prepared by the Presidents Council on Bioethics which took a relatively 
conservative stance on the ethics of enhancement technologies [105]. Others 
like Caplan have challenged arguments against enhancement with the more 
liberal view that cognitive enhancement could positively contribute to society 
[30-32]. Recently, Greely et al. published a commentary in Nature urging 
society to respond to a growing demand for cognitive enhancement and reject 
“the idea that ‘enhancement’ is a dirty word” [59]. In their commentary, Greely 
et al. suggest that cognitive enhancers “should be viewed in the same general 
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category as education, good health habits, and information technology- ways 
that our uniquely innovative species tries to improve itself.” In 2007 the British 
Medical Association examined the ethics of cognitive enhancement in a special 
report and asked many important questions [22].  Around the same time Nature 
sponsored an online survey to study cognitive enhancement practices [79]. This 
survey unleashed a flurry of correspondence showing that opinions on cognitive 
enhancement vary considerably [20, 47, 116, 123, 149]. There is far from any 
consensus regarding the ethics of enhancement. The ethical issues surrounding 
cognitive enhancement can impact individuals as well as the collectivity. The 
major ethical issues of enhancement will be described in the following section 
to illustrate the plurality of opinions on enhancement. 
Authenticity, identity and personhood  
Cognition enhancing treatments have been shown to have important 
effects in the treatment of neurodegenerative diseases likes Alzheimer’s 
disease. The effects of cognitive enhancers have not been completely elucidated 
in healthy individuals yet the previous section of this chapter outlined some 
ways cognition of healthy individuals can be modified. Enhancing any part of 
an individual’s cognition might also change their sense of self [22, 51, 57, 159]. 
This opinion reflects the belief that cognitive faculties like memory, mood and 
attention are integral parts of an individual’s self.  If indeed the identity of a 
healthy individual changes to a certain degree as a result of cognitive 
enhancement, the problem then is: which is the authentic individual? Is it the 
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enhanced individual or the unenhanced individual? A similar concern exists for 
parents of children with AD/HD [137].  Parents seem to be torn in determining 
whether the “real child” is that one that is able to “achieve their potential” with 
medication or the child whose behavior is not modified by methylphenidate.   
Some authors maintain that enhancement changes an individual because 
it bypasses the struggles of life such that “by reducing or eliminating 
shortcomings, biotechnological enhancement fundamentally alters the essence 
of what it means to be an individual” [25]. In response to the idea that cognitive 
enhancement is an affront to human nature it has been stated that “conveniences 
have eroded our collective character and cheapened us” [35]. Others contend 
that enhancement for all would eliminate some of the diversity in personal 
experiences and promote homogeneity in the population, i.e., reducing the 
diversity of identities [26]. These concerns are typically countered by two 
arguments. First, changes in our cognition already occur with little worry about 
authenticity for “neither are we the same person after a glass of wine as before, 
or on vacation as before an exam” [51]. Second, fears of a homogeneous 
population are considered speculative since there are as many uses for cognitive 
enhancers as there are individuals [56].  
Autonomy, individual rights and coercion 
 At first glance, cognitive enhancement of healthy individuals with 
neuropharmacology is largely elective. The term elective by no means reflects 
that performance enhancement is accepted or condoned but simply signifies 
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that an individual can choose to enhance their performance with a pill.  
However, as cognitive enhancement emerges and progresses in society the 
freedom individuals have to engage in or abstain from performance 
enhancement may diminish. As a result, discussions on the ethics of cognitive 
enhancement have raised the issues of autonomy and coercion in cognitive 
enhancement [22, 62, 86]. 
Considering the current framework for cognitive enhancement, 
individuals are left up to their own methods to procure cognitive enhancers. 
However, whether an individual’s motivation for obtaining 
neuropharmacological agents for enhancement is autonomous or the result of 
coercion is currently under debate. Arguments in favor of autonomous choice 
explain that “cognitively intact adults have a fundamental right to make the 
decisions that govern their lives.  Whether, and how, to enhance mental or 
physical functioning is one such choice” [25]. In this context, an individual’s 
choice to enhance their cognition would be considered as voluntary self-
improvement [32]. However, some stipulate that for such a decision to be truly 
autonomous, an individual must be aware of all risks associated with their 
cognitive enhancer of choice [35, 86, 153]. 
In contrast to the point of view that cognitive enhancement is an 
autonomous choice,  potential sources of coercion on an individual’s decision-
making have been identified [51]. On the one hand, pressures to enhance could 
be required or imposed by a specific context or environment like the workplace, 
academia, and the military [4, 36, 51, 151].  This type of coercion is perhaps 
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likely if cognitive enhancement becomes more widespread [51]. On the other 
hand, pressures to enhance could be much more subtle. Environments, like in 
academia, can constitute situations where even slight gains in cognitive 
performance can translate into substantial benefits. Athletes face a similar kind 
of coercion in that even though sports competitions openly call for honesty and 
fair play, some athletes still use performance-enhancing drugs [36]. 
Interestingly, although individuals may experience coercion from peers, 
colleagues and employers, a ban on cognitive enhancers could equally limit the 
autonomy of individuals representing a type of legislative coercion [62]. 
Justice 
The principle of justice is often evoked when discussing the ethics of 
the cognitive enhancement of healthy individuals. The chief concern is the 
equal distribution of neurotechnology with enhancement properties. 
Distributive justice is an important factor because cognitive enhancers: 
would be available only to the wealthy, or, if their cost were 
modest enough, to everyone but the poor. Those who were 
already relatively better off would gain the advantage of 
cognitive enhancement. The less well-off would fall further 
and further behind” [86].  
 
In this fashion, cognitive enhancement would widen the gap between the 
“have” and “have-not”.  However, some ethicists suggest that this kind of gap 
already exists in the “natural distribution of capabilities and disabilities” [125] 
[86, 153]. Accordingly, it has been proposed that distributive justice of 
cognitive enhancers may help bridge the gap created by the natural attribution 
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of talents [125].  However, as we mentioned in the discussion of lifestyle drugs 
above, it may not be appropriate to try to correct social injustices with 
neuropharmacology [77] especially when valuable healthcare resources are 
involved. 
 Natural talents set aside, the argument against the cognitive 
enhancement of healthy individuals based on unequal distribution is typically 
refuted by authors who evoke other injustices that are tolerated in our society. 
Other enhancements such as private tutoring and cosmetic surgery are not 
available to everyone but considered acceptable [51]. Moreover, Elliott has 
argued that: 
We live in a country where 46 million uninsured people cannot 
get basic medical care, while the rest of us spend a billion 
dollars a year on baldness remedies. It is not just the inequity 
here that is so impressive. It is the fact that we have gotten so 
accustomed to the inequity that we do not see it as obscene 
[30]. 
 
According to this point of view, distributive justice is not the ultimate ground 
for banning wider use of cognitive enhancers because society does accept other 
form of inequality. In addition, for some, equal distribution of cognitive 
enhancers does not ensure equal opportunities for all. A homogenous 
population of cognitively enhanced people would be competing for goods 
whose quantities remain unchanged and to which access is impeded by other 
socio-economic barriers thus solving one inequality but creating another [56]. 
However, this kind of situation may be avoided by the type of regulation that 
would govern access to cognitive enhancers [125] to allow for limited types of 
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enhancement. However, any type of regulation on cognitive enhancement must 
also consider the legal aspects related to the possession (which is illegal without 
a prescription) and distribution (also illegal to traffic prescription drugs on the 
black market) of neuropharmaceuticals with enhancing properties. 
Fairness and cheating 
The issue of fairness is distinct from distributive justice because is not 
related to access to cognitive enhancement but rather to the competitive aspects 
behind the demand for performance enhancement.  With respect to competition, 
cognitive enhancement can be perceived as a shortcut in achieving a goal [26, 
128]. By this measure enhancing one’s performance with neuropharmacology 
can be perceived as “cheating” [35, 62] especially when enhancers are not used 
by the whole population whether it be due to lack of access or by choice. These 
so-called shortcuts draw upon the issue of authenticity discussed earlier in this 
section because they “might also be undermining the value and dignity of hard 
work” [51]. A typical response to this argument is that “[y]ou deserve to win a 
Nobel Prize if you discover the cure for cancer, whether or not you do so with 
the aid of cognitive enhancement drugs” [86]. Consequently, cognitive 
enhancers can be praised for allowing individuals to reach their goals and 
positively contribute to society in terms of innovation and productivity [2, 127]. 
Fairness as an ethical issue in cognitive enhancement has often evoked 
comparisons to sports competitions and whether it is different from steroid use 
in athletes. One point of view is that what makes taking steroids unfair toward 
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other athletes who do not is that these substances are clearly banned from most 
sporting events [125, 128]. For example, in the absence of rules against using 
methylphenidate to write an exam, this form of cognitive enhancement cannot 
be considered unfair [125]. Another aspect of cognitive enhancement that has 
created ethical dilemmas is that it could be used to surpass so-called normal 
performance. A study by Sabini et al. shows that participants considered 
cognitive enhancement for high-performing individuals unfair but acceptable 
for lower-performing individuals [121]. Again, as with the issue of distributive 
justice, future debates and regulation on cognitive enhancement would be 
needed to establish uses of cognitive enhancement that are fair and unfair. 
Scientific data on the cognitive enhancement of healthy individuals 
 Some of the ethical discussion surrounding the cognitive enhancement 
of healthy individuals is based on the presumed efficacy and safety of cognitive 
enhancers in this population. As a result, Rose has expressed that: 
There is therefore no a priori reason — irrespective of ethical 
concerns or any other arguments — to suppose that, in the 
absence of pathology, pharmacological enhancement of such 
processes will necessarily enhance memory or cognition, 
which might already be 'set' at psychologically optimal levels 
[117]. 
 
It is not sufficient to presume that since these drugs produce an effect in 
patients that they will do the same in healthy individuals. Thus, it would be 
risky for cognitive enhancers to be used by healthy individuals without reliable 
data to support a significant benefit.  
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Some significant side effects are associated with the use of cognitive 
enhancers for medical reasons [49, 86]. For example donepezil can cause 
nausea, diarrhea, insomnia, fatigue, vomiting, muscle cramps, and anorexia. 
Consequently, some consider it unreasonable to expect an individual to incur 
any risk for a non-medical use of a neuropharmaceuticals “because the 
alternative is normal health” [35]. An earlier section of this chapter described 
how the cognitive enhancement of healthy individuals was related to 
prescription drugs abuse. Some of the drugs used for cognitive enhancement, 
like methylphenidate, have a high potential for abuse [148, 150] which 
represents another risk to evaluate [86]. The effects of neuropharmacology on 
healthy individuals may also pose an especially challenging task because 
“comparison to other comparably elective treatments such as cosmetic surgery, 
neurocognitive enhancement involves intervening in a far more complex 
system, and we are therefore at greater risk of unanticipated problems”[51].  
Researching all the risks of the non-medical use of 
neuropharmaceuticals is a tall order for neuroscience. However, this 
information is imperative to ensure that healthy individuals are not being 
exposed to any undue risk. One challenge for the neuroscience and ethics 
communities is the lay perception that prescription drugs are generally safe [73, 
101, 163]. Trust in prescription drugs comes from the perceived scientific rigor 
they must pass to be accepted. In the case of methylphenidate, safety is 
presumed because the drug is given to children which creates dangerous 
misunderstandings.  
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Broader implications 
The cognitive enhancement of healthy individuals can have a large and 
lasting impact upon social practices and institutions. Whitehouse explains these 
social implications by the hypothesis that “we cannot change ourselves without 
disturbing that larger web of identities” such that “personality changes are by 
necessity a community event and should be undertaken as such” [153].  For 
example, Farah et al. proposed that “when we improve our productivity by 
taking a pill, we might also be undermining the value and dignity of hard work, 
medicalizing human effort and pathologizing a normal attention span” [51]. On 
the other hand, it can be argued that “[j]ust as some plants can never live too 
long, and some animals can never have too many offspring, humans can never 
have too much cognitive experience” [153] considering the moral good it can 
bring in helping individuals reach their goals. Whether the cognitive 
enhancement of healthy individuals becomes widespread or not, it must be done 
in a way that does not encroach on the liberty of individuals in a democratic 
society [62]. 
 The fingerprint of each of the ethical issues discussed in this section can 
be seen in the potential future regulations around cognitive enhancement. For 
example, the authenticity of an individual could impact liability cases.  For 
example if an individual commits a crime while under the influence of a 
cognitive enhancer, might they be able to argue that they are not responsible for 
their actions? Future regulation could value distributive justice or ban cognitive 
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enhancers altogether. Academic institutions could create official rules with 
regard to the use of cognitive enhancers during examinations. The numerous 
ethical issues discussed highlight that “[t]he question is therefore not whether 
we need policies to govern neurocognitive enhancement, but rather what kind 
of policies we need” [51]. The challenge is to first determine which regulatory 
bodies should govern policy on cognitive enhancement and then to encourage 
responses [112] that will clarify the ethical issues that have elicited so much 
debate. 
Public understanding 
 
The ethical issues discussed in the previous section have shaped 
professional, academic and public health debates on the non-medical use of 
methylphenidate for the cognitive enhancement of healthy individuals. As these 
issues are discussed and “basic neuroscience is translated into therapies, 
practices and policies” [135] it becomes increasingly important to address the 
public understanding of the potential applications of neurotechnology. There is 
presently little data on how the public perceives the use of neurotechnology 
much less cognitive enhancement specifically. According to the US National 
Science Foundation, the American public seems to be generally enthusiastic 
with regard to the use of biotechnology [106]. This enthusiasm may be a 
reflection of belief in a “technological fix” for biological problems and the 
public’s faith in medicine [66]. However, a Brazilian survey on neuroscience 
literacy suggested that the public may know relatively little about basic 
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neuroscience [65]. This lack of neuroscience literacy which may lead to 
misinterpretations about how new neurotechnology can be applied and 
misapplied. This study also highlighted that some groups of participants who 
read newspapers and popular science magazines tended to have more general 
knowledge about that brain than those who didn’t.  
The media is a valuable source for the general public to learn health 
related information. It has been suggested that the impact of mass media upon 
the public is closely tied to personal experience and identity [132]. However, 
the type and degree of influence that the media may have on public 
understanding of health related information is a complex parameter to evaluate. 
Studies on the media are often approached in one of three ways in order to 
study either production of media reports, representation of information in media 
reports or reception of information by the media audience [132]. Studying the 
production of media reports sheds light upon why and how certain topics are 
covered. Some of the production of health reports in the media start with an 
understanding of what the audience is looking for. For example, the audience 
may be seeking accurate information regarding a certain health matter or 
novelty in the health field. Once a media report is produced, its representation 
in various forms can be studied to examine “discursive dominance of particular 
themes and constructions” in relation to “whether messages are likely to 
promote or damage health” [132]. Representation of a health topic may also 
vary as a function of its source (e.g., newspapers, special interest magazines, 
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television reports) potentially impacting audiences differently. The reception of 
media reports reflects how representations of a topic are perceived and 
understood by the public. Insight on how information is received by one or 
multiple audiences can ultimately affect how a media report is produced and 
represented [133]. 
A health topic need not be entirely new for it to be novel and relevant 
media report. With the use of media “templates” [132] in representations of 
health information, a recent occurrence can be portrayed as similar to a previous 
event that sparked debate in the media. This kind of “scandal narrative” [134] 
allows the audience to recognize a recurrent topic in a slightly different context. 
For example, in a study on UK media portrayals of banking children’s tissue, 
Seale et al. found that “everything to do with body parts and tissues was 
incorporated into the organ retention template” [134]. A common media 
template in health reporting covers the dangers of modern life [132] which has 
started to include discussions of medicalization and associated uses of 
pharmaceuticals. The use of modafinil, a drug that is associated with cognitive 
enhancement, to regulate sleep is a topic related to this media template. Studies 
have found that media discourses on modafinil and sleep reflects increasing 
pressures to “pursue a healthy, successful and well-adjusted life in a modern 
world that is increasingly unfriendly towards ‘natural’ sleep rhythms” [133]. On 
one hand, modafinil is constructed as a “wonder drug” [156] and commodity 
that can help control sleep [42] whether for treatment or enhancement purposes. 
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Modafinil then gains interest as novelty. On the other hand, media discourses on 
this topic have also expressed cultural and social concerns about regulation of 
sleep cycles with modafinil especially for enhancement purposes [42, 156]. In 
turn, the apprehension about non-medical uses of this drug to cope with the 
demands of modern life portrays modafinil as scandalous. Though the reception 
of media discourses on modafinil and sleep remain to be examined the 
representation of this topic according to a media template which highlights both 
novelty and scandal may influence how the public perceives and understands 
the non-medial use of other drugs for performance enhancement. 
 The public is being exposed to increasing amounts of information about 
developments and applications of neurotechnology through media coverage. 
Cognitive enhancement, deep-brain stimulation and neuroimaging have all been 
featured in the print media [101, 108, 109, 114] and other means of 
communication like television and radio. In addition, the Internet is proving to 
be an emerging influence on the public understanding of neurotechnology 
[113]. Despite prevalent coverage the public may feel that they are not properly 
informed of advances in neurotechnology [106]. Indeed, media reports on 
emerging uses of neurotechnology are associated with overstating benefits 
through optimistic headlines [114, 118] and general reporting [109, 111, 114]. 
The media may also be prematurely predicting the impact of research results 
[131]. Enthusiastic media reports may foster misunderstanding in the public 
painting a: “skewed picture of biomedical research a picture that emphasizes 
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benefits over risks and predictions of unrealistic breakthroughs on a tempered 
explanation of the incremental nature of the advancement of scientific 
knowledge”  [33]. 
The media plays a role in public understanding but it is also part off the 
commercialization of neurotechnology. According to some, the media is 
associated with a commercialization agenda which can lead to patenting issues, 
marketing pressures, commercialization pressures, and general hype [34].  
Some consider media reports a form of direct-to-consumer advertising (DTCA). 
For example, Zuckerman considers that “medical news is actually unpaid 
advertising” [164]. A host of neuroproducts like natural neuroproducts, 
neuropharmaceuticals and neuroimaging services are being marketed to 
consumers over the Internet [113]. DTCA has been found to have profound 
effects upon the ways consumers perceive the utility of medical products [90, 
91]. Some of these effects may be positive. For example, DTCA may promote 
lay empowerment [132] and informed decision-making in the public because 
information is reaching them directly. However, this is not likely to be the case 
when media reports “present medical information in a way that exaggerates 
disease risk and thus the value of the marketed products in reducing that risk” 
[130].  
The media is potentially further implicated in the commercialization of 
neurotechnology simply in what they choose to cover. By choosing to cover 
developments in neurotechnology and indirectly marketing them, the media 
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may be contributing to a reorientation of research to develop products that can 
be commercialized [34]. Commercialization is likely to be an important issue in 
the future of the non-medical use of neuropharmaceuticals for cognitive 
enhancement depending, of course, upon the policies surrounding the 
phenomenon. Reporting on neurotechnology also works in the media’s favor. 
When publishing research of interest to the public they increase interest in their 
publication, broadcast or website [23]. In turn, commercialization interests feed 
into “hype” around the results of neuroscience research therefore the media’s 
translation of knowledge is not always at the root of hype surrounding 
neurotechnology. Interestingly, a study by Bubela and Caulfield of newspaper 
coverage on genetic research found that most of the basic information about the 
results of research was accurate [24]. Caulfield has argued that the hype 
generated by the media may be a “faithful portrayal of commercially influences 
research results” [33] and not exclusively sensationalist reporting by journalists 
themselves.  
Public engagement is a good approach to promote public understanding 
of a subject, like the non-medical use of neuropharmaceuticals for performance 
enhancement, which can be defined in many ways. Public engagement can 
render the public more critical of reports on advances in neuroscience while 
extracting the different perspectives and interests of stakeholders. Schwartz and 
Woloshin have suggested ways for the public to be more critical of medical 
advertisement and by extension media reports on neurotechnology. These 
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strategies include being aware of research parameters like sample sizes and the 
timeframe of reported benefits and risks [130].  
Possibly one of the most interesting suggestions for public engagement 
is the progression from unidirectional to multidirectional communication of 
neuroscience research. Science reporting is typically viewed as unidirectional in 
that research is processed by the media through knowledge translation which 
them produces a headline that the public reads [110]. A unidirectional discourse 
around science is often created because science can be considered a “discourse 
of experts” [110, 118]. However, public engagement regards science as a 
community inclusive of experts and non-experts [110]. When science becomes 
a community discourse the communication becomes multidirectional and thus a 
communication of “science to its publics and the communication of publics to 
their scientists” [118]. In the multidirectional concept of science not only is the 
public aware of the benefits and limits of research but they can also express 
opinions and concerns about its applications.  As cognitive enhancement gains 
notoriety and possibly prevalence, public understanding and engagement will 
likely be an important task on the way to determining any kind of policy. This 
being said, this thesis addresses some of the key ethical and social issues of 
cognitive enhancement with a focus on current discourses. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Methodological approaches 
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This research aimed to analyze discourses on the non-medical use of 
MPH to enhance cognitive and academic performances. We examined 
discourses on the non-medical use of MPH in the print media (PM), bioethics 
literature (B), and public health literature (PH) based on the work in Chapter 4 
suggesting significant differences. 
Sampling 
We generated the print media sample for this study using Factiva and 
LexisNexis Academic, two databases designed for documentation research. 
Factiva specializes in business resources while Lexis-Nexis specializes in law 
resources. Both databases provide access to full-text news reports both print 
(newspaper, magazines and wire reports) and broadcast (transcripts of 
television and radio). We searched for English language newspaper articles 
published from 01/01/2000 to 11/14/2006 using guided news search options 
[109]. The start date of 2000 was chosen given the report of non-medical use of 
MPH in college students in the early 2000s [11]. The print media sample was 
restricted to newspaper articles in order to decrease variance in length and 
general interest. Magazine and news wire pieces may be much longer and 
tailored to a specific audience. Multiple keyword searches were used to identify 
articles discussing the non-medical use of MPH (Table 2-1). Keywords were 
searched in headline, lead paragraph(s) and general news (major papers) in both 
Factiva and LexisNexis Academic databases to maximize coverage. Bioethics 
and public health publications were sought using standard databases (Appendix 
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I). All articles yielded by the searches were carefully examined for relevance, 
the key criteria being the discussion of the non-medical use of MPH. Individual 
articles were the sampling units. 
Table 2-1: Generation of sample for analysis of discourses on the non-medical 
use of methylphenidate  
* We found a single article repeated four times (N=23 articles) but kept the 
twenty distinct articles for analysis (except for the headline analysis since all 23 
headlines were distinct.) 
† Articles originated from USA (n=11), UK (n=6), Australia (2) and Canada 
(1). 
 
Coding 
The content of all articles was coded systematically using the QSR 
NVivo 7 software (Doncaster, Australia). The inductively-generated coding 
guide and grid were inspired by previous content analyses of print media [108, 
109, 111] but adapted to our object of research, discourses on the non-medical 
use of methylphenidate. Previous content analyses have examined features of 
the media coverage on certain types of research such as genomics [111] and 
brain imaging [108, 109]. These studies had examined the general type and tone 
of the media articles in their sample. The type of article referred to the style in 
Discourse Databases Keywords Articles  (n) 
Print 
media 
Lexis-Nexis 
Academic 
Factiva 
20*† 
Bioethics 
literature 
PubMed 
(bioethics limit) 
Expanded Academic 
14 
Public 
health 
literature 
PubMed 
Expanded Academic 
“ritalin” 
“methylphenidate” 
“smart drugs” 
“ritalin & study aid” 
“cognitive 
enhancement” 
“neuroethics” 
“stimulant abuse” 
“non-medical use” 
“illicit use” 
7 
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which the information about scientific research is presented in the article. These 
studies noted whether the article was strictly informative or if the article 
contained some type of reflection or critique on the research presented. The 
tone of the article referred to the attitude adopted by the article with regard to 
the research reported upon. Tone was classified as positive (advantages), 
balanced (advantages and disadvantages), neutral (no advantages or 
disadvantages) or critical (disadvantages). However, in the present study, some 
of the sample consisted of original research rendering assessment of features 
like the type and tone of an individual article less applicable. Research articles 
are necessarily informative and reflective in that they must discuss the limits of 
their ideas and research, implications of their findings as well as future 
questions to investigate. Furthermore, these studies largely indicated the 
presence or absence of certain features but put less emphasis on qualitative 
analysis of these features. For example, the number of articles that had a 
positive tone was recorded but the topics that made the tone of the article 
positive were not. With the exception of the study by Racine, Bar-Ilan and Illes, 
the same is true for the ethical issues. The mention of ethical issues was 
quantified but whether the issue was favorably or unfavorably discussed did not 
figure into the data analysis of these studies. The coding guide used to in our 
study was designed to extract this type of qualitative feature. 
Adaptation of the coding guide was pursued through multiple rounds of 
piloting and test coding on a sub-sample of 10 print media articles to ensure 
validity and robustness [95]. Key codes were derived through an inductive 
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process in which previously used coding categories for content analysis [111] 
were refined and adjusted to the context of non-medical use of MPH. This 
coding guide defined each category and provided both an explicit (upper limit) 
and implicit (lower limit) example of what each code could be applied to 
(Appendix II). After the initial coding of the whole sample by one member of 
the research team, two other members of the research team reviewed the 
content of each category to ensure reliability of coding by consensus and ensure 
that each code was within the limits established by the coding guide. The final 
coding structure included four major areas (Table 2-2): (1) description of the 
non-medical use of MPH; (2) workings and effects of MPH, including positive 
and negative effects associated with non-medical use of MPH; (3) description 
of ethical, social, and legal issues associated with non-medical use of MPH and 
(4) recommendations for the prevention of the non-medical use of MPH. 
Coding of the ethical, legal and social content was furthered by determining if 
the coded statements affirmed, negated, or remained neutral or ambivalent 
regarding the issue at stake.   
Our goal for this study was to examine the representation of different 
ethical, social and legal issues surrounding the non-medical use of MPH.  The 
statements coded from print media, bioethics and public health articles were 
subject to content analysis which is a “systemic, objective, quantitative analysis 
of message characteristic” [95]. We used basic descriptive statistics to report 
the frequency and distribution of various codes as an indication of which 
themes were emphasized in each discourse. However, examining various 
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representations of the non-medical use of MPH also required a qualitative 
analysis of content. Thus, we carried out a discourse analysis of our sample 
(print media, bioethics literature and public health literature) which is better 
suited to qualitatively typify different representations of a phenomenon [95]. In 
turn, comparison of coded statements was carried out within a discourse instead 
of within an individual article. As a result, sections of text were dissociated 
from each article and grouped with other statements pertaining to a certain 
theme (see coding guide). A similar organization of discourse content was 
carried out in studies on the representation of modafinil in the UK media [42, 
156]. Structuring the discourse analysis in such a way allowed us to avoid 
associating a certain representation with the opinion or research of a particular 
journalist or author.  However, previous studies have approached discourse 
analysis in different ways. Coveney et al. coded content into already established 
metaphors and media frameworks regarding modafinil to identify sub-themes 
whereas our study applied the same coding guide to each discourse in order to 
observe any framework constructed by the themes we identified. Coding of 
discourse content in the Williams et al. study on modafinil in the media 
concentrated largely on the language used (e.g., key words and phrases, 
vocabulary used to address reader, rhetorical styles and emotional overtones) in 
part to interpret how the media articles should be read. We analyzed language 
used to describe the non-medical use of methylphenidate but the themes we 
generated in our coding guide were more diverse in scope. Our approach 
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allowed to illustrate the nature of statements found within discourses and also 
to contrast discourses on the non-medical use of MPH.  
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Table 2-2: Coding structure used to analyze media, bioethics, and public health 
discourses on the non-medical use of methylphenidate (MPH) 
Section 1: Description of non-medical use of MPH 
1.1. Definitions and synonyms for non-medical use of MPH 
 Formal definition of non-medical use of MPH 
 Lay descriptions of non-medical use of MPH 
 Distinction between treatment and enhancement 
1.2. Uses of MPH 
 Medical use 
 Cognitive and academic performance enhancement use 
 Recreational use 
1.3. Aims of cognitive enhancement 
1.4. Extent of non-medical use of MPH 
Accepted 
Frequent 
Neutral 
Questionable 
 
Rare 
1.5. Description of practices of non-medical use of MPH 
 When is MPH used non-medically 
 Who is using MPH non-medically 
 Where is MPH used non-medically 
 How MPH is procured for non-medical use 
 Black market 
 Buying pills from other students 
 Feigning symptoms of ADHD 
 Online pharmacies 
 Other 
1.6. Types of non-medical uses reported 
 Methylphenidate 
 Other neuropharmaceuticals 
 Non neuropharmaceutical 
 Other 
Section 2: Workings and effects of MPH 
2.1. How MPH works 
2.2. Physiological effects of non-medical use of MPH 
 Physiological negative effects of non-medical use of MPH 
 Physiological positive effects of non-medical use of MPH 
2.3. Psychological effects of non-medical use of MPH 
 Psychological negative effects of non-medical use of MPH 
 Psychological positive effects of non-medical use of MPH 
2.4. Unknown effects of non-medical use of MPH 
2.5. Information on ADHD 
 Nature of ADHD 
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 Prevalence of ADHD 
Section 3: Ethical, social and legal issues associated with non-medical use of MPH * 
3.1. Abuse 
3.2. Authenticity, identity, and personhood 
3.3. Autonomy, individual rights, and informed consent 
3.4. Cheating 
3.5. Commercialization 
3.6. Illegality 
3.7. Injustice, access, and equality 
3.8. Overprescription 
3.9. Regulation and governance 
3.10. Reliability of scientific research 
3.11. Safety  
3.12. Social meaning 
3.13. Social integration and acceptability  
Section 4: Prevention of non-medical use of MPH and related challenges 
4.1 Solutions 
4.2 Challenges 
*Content under these codes was further analyzed into 3 coding options: (1) 
affirmation of the issue; (2) negation of the issue; (3) neutral or ambivalent stance 
regarding the issue with the exception of ‘Regulation and governance’ whose content 
was not suited for this kind of analysis and presented with recommendations for 
prevention. 
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Cognitive enhancement can be defined as an emerging practice whereby 
healthy individuals improve their cognitive functions such as perception, 
attention, memory and reasoning with neuropharmacological agents that are 
otherwise used for the treatment of pathological conditions. 
The emergence of cognitive enhancement has been gradual and is 
generally associated with the off-label use of prescription drugs. 
Research has also indicated possible venues for cognitive enhancement. 
In 2002, Yesavage et al. conducted a study where middle-aged licensed aircraft 
pilots were given donepezil. By monitoring the pilots’ performance on a flight 
simulator the investigators found that the pilots were able to better retain 
information when given the drug [7]. 
Studies have found that memory consolidation can also be influenced by 
beta-adrenergic blockers [4]. These drugs are being tested as inhibitors of 
memories to prevent the onset of post-traumatic stress disorder. 
Modafinil regulates sleep/wake cycles in patients suffering from 
conditions like narcolepsy and sleep apnea. However, 90 per cent of 
prescriptions for modafinil are for off-label purposes- for example, to increase 
alertness in people without chronic sleep problems [6]. 
The emergence of cognitive enhancement 
Perhaps the most compelling contemporary example of cognitive 
enhancement is the use of methylphenidate by students who do not suffer from 
attention deficit/hyperactivity disorder (ADHD).  
60 
  
Methylphenidate’s effectiveness in controlling the symptoms of ADHD 
raised its popularity within the healthcare system. Its production increased by 
nearly 900 per cent from 1990 to 2000 in the Unites States [3]—making Ritalin 
a household name. 
The rates of methylphenidate abuse and other ADHD medications reported by 
studies on the illicit use of prescription drugs among college students are 
variable. However, consensus exists as to their actual diversion. Recreation and 
experimentation aside, non-ADHD students are using methylphenidate to 
enhance concentration and alertness with the hope of achieving better academic 
performance [3, 5]. 
There is little evidence on the long-term effect of illicit methylphenidate 
use on a student’s academic performance [3]. Nonetheless, the testimonials of 
users in the popular press hail methylphenidate as a “study aid” more potent 
and effective than coffee or energy drinks, which are now considered relics of 
the past.  
Correlations between the stringency of admission criteria and the 
prevalence of methylphenidate abuse show that, in general, the higher the 
admission criteria, the more likely students will turn to cognitive enhancement 
[5]. The apparent social pressure on these students to perform, combined with 
the potential harm of drug abuse, fuels the ethical debate as this practice enters 
mainstream society. 
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A second look at the ethics of cognitive enhancement 
A child with ADHD can benefit from treatments, and in turn, build the 
foundation of his education and future. How then is the cognitive enhancement 
of a “normally” functioning person justified?  
The ‘liberal’ approach to this issue is typically based on autonomy and 
individual rights. Proponents of liberalism regard cognitive enhancement as a 
personal choice to self-improve, which does not infringe upon another’s right to 
do the same or to abstain.  
In this sense, the ethical reasoning behind cognitive enhancement is 
much like that which supports the socially accepted practice of cosmetic 
surgery. Hence, the liberal view of cognitive enhancement suggests that one can 
use technology and medicine as a morally justified means of self-achievement.  
The ‘conservative’ (for lack of a better name) approach towards the 
debate on cognitive enhancement expresses concerns that the practice threatens 
“essential characteristics of what it means to be human” [1]. Alteration of 
cognition could disturb one’s concept of ‘self’ [1, 2], thus creating a new or 
different person—an inauthentic self. Cognitive enhancement could also 
represent a form of cheating like the use of performance-enhancing drugs in 
sport. Other important issues include safety, dependence and public health. 
Cognitive enhancement should be available to all according to the 
liberal approach. However, the conservative view cautions about distributive 
62 
  
justice and its impact on the common good because there could be as many uses 
for cognitive enhancement as there are individuals.  
Furthermore, equal access to neuropharmacological agents would not 
ensure equal opportunities for all. A homogenous population of cognitively 
enhanced people would be competing for goods whose quantities remain 
unchanged and to which access is impeded by other socio-economic barriers. 
The social integration and acceptance of cognitive enhancement is 
emerging. Perhaps future neuroscience research will support other possible 
cognitive enhancements. The time is therefore ripe to reflect upon the kinds of 
approaches needed to guide social practice.  
In the present context, physicians are the gatekeepers to the drugs used 
for cognitive enhancement. The liberal approach might call to maintain the 
status quo or declare a free market laissez-faire attitude on cognitive enhancers.  
On the other end of the spectrum, should the debate over cognitive 
enhancement be settled with a moratorium on research, development and 
prescription of drugs associated with cognitive enhancement practices? Then, 
the cure could become much worse than the disease.  
Could future policies rest upon a middle ground between individual 
rights and autonomy on the one hand, and the common good on the other? 
Broad social discussion on the ethics of cognitive enhancement should resume 
so as to foster public appreciation of the upcoming medical, ethical and social 
challenges, and the immediate need for informed debates [8]. 
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Abstract 
The prospects of enhancing cognitive or motor functions using 
neuroscience in otherwise healthy individuals has attracted considerable 
attention and interest in neuroethics . The use of stimulants is one of the areas 
which has propelled the discussion on the potential for neuroscience to yield 
cognition-enhancing products. However, we have found in our review of the 
literature that the paradigms used to discuss the non-medical use of stimulant 
drugs prescribed for attention deficit/hyperactivity disorder (ADHD) vary 
considerably. In this brief communication, we identify three common 
paradigms – prescription drug abuse, cognitive enhancement, and lifestyle use 
of pharmaceuticals – and briefly highlight how divergences between paradigms 
create important “ethics blind spots”. 
 
Background 
The use of prescription pharmaceuticals for reasons other than those 
medically intended, commonly called “prescription drug abuse” represents a 
potentially growing health problem. In the United States (US), 48 million 
individuals over the age of 12 have used1 non-medically a wide range of 
prescription drugs from central nervous system (CNS) depressants and opioids 
to stimulants [10]. The documented non-medical use of prescription stimulants 
(e.g., methylphenidate) in particular has been found to range from 5% to 35% 
in surveys of North American young adult and adolescent populations [13]. 
Rates for non-medical use of stimulants to specifically improve academic 
performance range from 3% to 11% in college students (reviewed in Table 4-1). 
Similar patterns of prescription use have recently been reported in a Nature-
                                                 
1 In this paper, we use the term “non-medical use” to: (1) reflect the fact that the uses we refer 
to are not medically approved and (2) differentiate it from the prescription drug abuse and 
cognitive enhancement paradigms that we are discussing. We are aware that there are no neutral 
and value standpoint terminology on this issue. 
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sponsored survey where 20%  (N=288/1427) of respondents reported having 
used drugs non-medically to improve concentration, focus and memory [9]. 
Methylphenidate was the most commonly used drug in that survey (62%; 
N=132/214). Potential contributing factors to the spread of non-medical 
prescription use include the low cost of prescription drugs relative to illegal 
drugs, the availability of drugs through several channels other than traditional 
prescription, and the emergence of on-line pharmacies [10]. Consequently, the 
non-medical use of pharmaceuticals has created a source of growing medical 
and ethical problems. Currently, various paradigms are employed to approach 
non-medical prescription use reflecting a wide range of views and ethical 
opinions. 
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Table 4-1: Brief review of studies reporting prevalence rates of lifetime non-medical prescription stimulant (NMPS) use and PS use specifically for 
cognitive enhancement (CE) in college student populations 
Study Sample population NMPS use (%) NMPS use for CE (%)* 
Teter et al. Pharmacotherapy. 2006 4580 college students in a large Midwestern university 8.3 
5.4 (enhance concentration) 
5.0 (enhance studying) 
4.0 (enhance alertness) 
Prudhomme White et al. J Am Coll Health. 2006 1 025 students at the University of New Hampshire 16.2  
11.0 (enhance concentration) 
8.7 (enhance studying) 
3.2 (enhance grades) 
Teter et al. J Am Coll Health. 2005 9161 undergraduate students at the University of Michigan 8.1 
4.3 (enhance concentration) 
3.2. (enhance alertness) 
Hall et al. J Am Coll Health. 2005 381 college students from the University of Wisconsin-Eau Claire 13.7 3.7 (enhance studying) 
Graff Low & Gendaszek, Psychol Health Med. 2002 150 undergraduate students at a small, competitive college in the US 35.3 
8.2 (enhance intellectual 
performance) 
7.8 (enhance studying) 
*Our own calculation based on data presented in the studies 
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The prescription drug abuse paradigm 
Most public health studies on the nature and prevalence of non-medical 
use of prescription stimulants name the phenomenon “prescription drug abuse”. 
This paradigm expresses concerns for the health of individuals engaging in 
those practices and highlights the health risks and potential for dependence 
associated with the non-medical use of drugs like methylphenidate. However 
this paradigm has a number of important drawbacks such as applying the harsh 
language of illicit drug abuse to pharmaceuticals while some of the actors and 
contexts involved are markedly different. For example, a black market does 
exist for prescription drugs but students also resort to feigning symptoms of 
attention deficit/hyperactivity disorder (ADHD) in order to obtain 
methylphenidate from doctors. Further, the strong stance against non-medical 
prescription use in the abuse paradigm may not fully convey the ambivalence in 
the medical and bioethics communities as well as in the general public 
regarding the ethics of this practice. In fact, competing paradigms (reviewed 
below) express some enthusiasm for the beneficial effects of non-medical use 
of pharmaceuticals [2, 3].  
The cognitive enhancement paradigm 
In the bioethics literature the term “prescription drug abuse” is rarely 
encountered and much of the discussion surrounding the non-medical use of 
pharmaceuticals is based on descriptions of the phenomenon as “cognitive 
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enhancement” or “performance enhancement” (e.g., President's Council on 
Bioethics in the US; discussion paper of the British Medical Association [2, 
12]). In contrast to the first paradigm, this one incorporates the potential 
benefits of increasing cognitive function beyond ordinary or average capacities 
[1]. Because of this focus, the enhancement paradigm has highlighted the 
potential impact on the individual per se addressing issues related to identity 
and personhood (are we the same with or without performance-enhancement 
drugs), autonomy (will we be coerced into abusing prescription drugs to 
compete with others if enhancement practices become widespread), and the 
meaning of medicine (is it within the purview of medicine to enhance and not 
only treat). However, from a medical and scientific perspective, describing the 
phenomenon as “enhancement” does not resonate with the unknown risks of 
long term non-medical use of prescription drugs. Accordingly, this paradigm 
has generated many polarized debates framed as “to enhance or not to enhance” 
while paying less attention to the conditions under which enhancement of 
function could become ethically acceptable (e.g., obtaining evidence about 
long-term side-effects; assessing risks of dependence). Strikingly, the 
interdisciplinary bioethics community is not in tune with the more critical 
public health perspectives and this perhaps partly reflects why some 
enthusiastic portrayals of non-medical prescription drug use are encountered in 
the bioethics literature. 
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The lifestyle use of pharmaceuticals paradigm 
Finally, the “lifestyle” paradigm constitutes a third and less technical 
paradigm is employed occasionally in the scientific literature but with greater 
emphasis in the public domain. The description of the non-medical use of 
prescription drugs as a “lifestyle choice” transforms “prescription drugs” into 
“lifestyle drugs”. The lifestyle paradigm expresses the optimistic belief that 
pharmaceuticals can not only help individuals face illness but help them “be all 
that they can be” based on their own decisions and goals. Instances of this 
paradigm are found in the media where the non-medical use of stimulants like 
methylphenidate, for example, are designated as “better living through 
chemistry” [14] and methylphenidate dubbed a “study aid” [11], a “brain 
steroid” [5], and a “smart drug” [5, 11]. This paradigm thus expresses lay 
understandings of non-medical use of drugs and illustrates the current 
ambivalence regarding the medical and ethical nature of this practice. This is 
reflected in the provocative comparison of Ritalin to, “study tools, just like 
tutors and caffeine pills” [7].  The lifestyle paradigm suggests that the emerging 
non-medical uses of pharmaceuticals reflect an individual choice of citizens 
living in liberal democratic societies marked by medical consumerism. 
Accordingly, it is no longer necessary to “frequent the dark corners of 
campuses to come across a student drug that is fast growing in popularity” [11]. 
Though the lifestyle paradigm expresses the social acceptance that non-medical 
drug use is gaining outside the medical community, referring to 
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pharmaceuticals using metaphors like “miracle drug” [8] in the media is likely 
to convey inappropriately that non-medical prescription use is a safe and 
acceptable practice in spite of unknown risks. Hence, this paradigm is perhaps 
the most challenging for the medical and ethics communities because its view 
of the role of pharmaceuticals for self-achievement deviates from the common 
understanding of pharmaceuticals as treatment prescribed for illness.  
Divergence between paradigms creates ethics blind spots 
The existence of distinct paradigms for approaching the non-medical 
use of pharmaceuticals clearly shows the lack of consensus on the acceptability 
of the practice. However, paying attention to diverging paradigms can help 
identify some important “ethics blind spots”. On the one hand, favorably 
describing non-medical prescription use as “enhancement” and the use of 
methylphenidate as a “study aid” or a “lifestyle choice” may lead to the 
unintended dissemination of non-medically approved practices based on 
misinterpretations. The media in particular has adopted sensationalist language 
to describe the lifestyle impact of non-medical prescription use while bioethics 
scholarship has already heavily and optimistically labeled the practice 
“enhancement” without clear scientific evidence and knowledge of long-term 
risks. On the other hand, the lack of acknowledgment of growing public 
enthusiasm for non-medical prescription use could lead public health 
interventions astray. This is likely to happen if such interventions are based 
solely upon the prescription drug abuse paradigm and neglect the social 
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acceptance of non-medical prescription use found in the enhancement and 
lifestyle paradigms. Indeed, what may be viewed as problematic from a public 
health perspective (i.e., viewed as prescription abuse) may have already started 
becoming legitimate in the public domain (i.e., viewed as “cognitive 
enhancement” or a lifestyle choice). To better understand the ethics 
ofperformance-enhancement drugs at a social level, further research will be 
needed to determine which paradigm or which combination of paradigms 
reflects the views of stakeholders such as lay citizens, healthcare professionals, 
and public health authorities. 
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Abstract 
 
There is substantial evidence that methylphenidate (MPH; Ritalin), is 
being used by healthy university students for non-medical motives such as the 
improvement of concentration, alertness, and academic performance. The scope 
and potential consequences of the non-medical use of MPH upon healthcare 
and society bring about many points of view.  To gain insight into key ethical 
and social issues on the non-medical use of MPH, we examined discourses in 
the print media, bioethics literature, and public health literature.  Our study 
identified three diverging paradigms with varying perspectives on the nature of 
performance enhancement. The beneficial effects of MPH on normal cognition 
were generally portrayed enthusiastically in the print media and bioethics 
discourses but supported by scant information on associated risks. Overall, we 
found ambivalence regarding ethical, legal and social issues related to the non-
medical use of MPH for performance enhancement and its impact upon social 
practices and institutions. The exception to this was public health discourse 
which took a strong stance against the non-medical use of MPH typically 
viewed as a form of prescription abuse or misuse. Wide-ranging 
recommendations for prevention of further non-medical use of MPH included 
legislation and increased public education. Some positive portrayals of the non-
medical use of MPH for performance enhancement in the print media and 
bioethics discourses could entice further uses. Medicine and society need to 
prepare for more prevalent non-medical uses of neuropharmaceuticals by 
fostering better informed public debates. 
 
 
Background 
The non-medical use of neuropharmaceuticals is generating substantial 
debates in medical and public health circles [7, 10]. A key motive for this non-
medical use of neuropharmaceuticals is the enhancement of cognitive function 
in healthy individuals beyond normal human capacity [18, 19, 38]. There is 
substantial evidence that methylphenidate (MPH; Ritalin), a drug prescribed to 
manage the symptoms of Attention Deficit/Hyperactivity Disorder (AD/HD) in 
children and adults, is being misused by healthy university students to improve 
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concentration, alertness, and academic performance [51].  
Methylphenidate is one of the most commonly used stimulants in the 
management of AD/HD symptoms [9, 52]. Academics and stakeholders have 
debated its prescription, and overprescription, making this stimulant a familiar 
name for healthcare providers and the public. However, the debate on 
performance enhancement differs in that MPH is now being used for reasons 
unrelated to AD/HD. Furthermore, performance enhancement is distinct from 
“off-label” uses by physicians because performance enhancement uses are 
neither medically prescribed nor supervised. Recent studies have reported that 
this form of performance enhancement is a reality affecting North American 
university campuses. Studies of prevalence rates show a range from 6.9% [30] 
to 35.3% [21] for prescription stimulant misuse in this student population. 
Closer examination of the motives behind the non-medical use of prescription 
stimulants yields rates from 3.2 % up to 11% for the specific goals of improving 
concentration, alertness and academic performance [38]. Consequently, some 
scholarly ethical debates on the non-medical use of MPH have surfaced notably 
because: “In contrast to the other neurotechnologies […] whose potential use 
for enhancement is still hypothetical, pharmacological enhancement has already 
begun.”[18]  
The scope and potential consequences of the non-medical use of MPH 
upon healthcare and society are wide-ranging and bring about many points of 
view and various discourses. In particular, media discourses can have important 
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consequences on the practice of frontier health intervention and human welfare 
by shaping ethical debates and influencing public acceptance of 
neurotechnological innovation [16, 41]. Accordingly, many fear that the public 
misunderstands the promises of neuroscience and their limitations [14, 44] 
based on exaggerated or unbalanced media accounts. Consequently, it is 
important to examine the debate on pharmacological performance enhancement 
in the public sphere. This paper reports the results of a study which aims to 
review and compare print media coverage with existing bioethics and public 
health discourses on the non-medical use of MPH for performance 
enhancement. We hope thereby to gain insights into key ethical and social 
issues of this emerging practice. 
Methods 
This research aimed to analyze discourses on the non-medical use of 
MPH to enhance cognitive and academic performances. We examined 
discourses on the non-medical use of MPH in the print media (PM), bioethics 
literature (B), and public health literature (PH) based on previous work 
suggesting significant differences [38]. 
Sampling 
We generated the print media sample for this study using the Factiva 
and LexisNexis Academic databases consisting of full-text news, business, and 
law resources. We searched for English language newspaper articles published 
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from 01/01/2000 to 11/14/2006 using guided news search options [37]. The 
start date of 2000 was chosen given the report of non-medical use of MPH in 
college students in the early 2000s [3]. Multiple keyword searches were used to 
identify articles discussing the non-medical use of MPH (Table 5-1). Keywords 
were searched in headline, lead paragraph(s) and general news (major papers) 
in Factiva and LexisNexis Academic databases. Bioethics and public health 
publications were sought using standard databases. All articles yielded by the 
searches were carefully examined for relevance, the key criteria being the 
discussion of the non-medical use of MPH. Individual articles were the 
sampling units. 
Table 5-1: Generation of sample for analysis of discourses on the non-medical 
use of methylphenidate  
 
Discourse Databases Keywords Articles  (n) 
Print 
media 
Lexis-Nexis 
Academic 
Factiva 
20*† 
Bioethics 
literature 
PubMed 
(bioethics limit) 
Expanded Academic 
14 
Public 
health 
literature 
PubMed 
Expanded Academic 
“ritalin” 
“methylphenidate” 
“smart drugs” 
“ritalin & study aid” 
“cognitive 
enhancement” 
“neuroethics” 
“stimulant abuse” 
“non-medical use” 
“illicit use” 
7 
* We found a single article repeated four times (N=23 articles) but kept the 
twenty distinct articles for analysis (except for the headline analysis since all 23 
headlines were distinct.) 
† Articles originated from USA (n=11), UK (n=6), Australia (2) and Canada 
(1). 
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Coding 
The content of all articles was coded systematically using the QSR 
NVivo 7 software (Doncaster, Australia). The inductively-generated coding 
guide and grid were inspired by previous content analyses of print media [36, 
37, 39] but adapted to our object of research. Adaptation of the coding guide 
was pursued through multiple rounds of piloting and test coding on a sub-
sample of 10 print media articles to ensure validity and robustness [32]. Key 
codes were derived through an inductive process in which previously used 
coding categories for content analysis [39] were refined and adjusted to the 
context of non-medical use of MPH. This coding guide defined each category 
and provided both an explicit (upper limit) and implicit (lower limit) example 
of what each code could be applied to. After the initial coding of the whole 
sample by one member of the research team, two other members of the research 
team reviewed the content of each category to ensure reliability of coding by 
consensus and ensure that each code was within the limits established by the 
coding guide. The final coding structure included four major areas (Table 5-2): 
(1) description of the non-medical use of MPH; (2) workings and effects of 
MPH, including positive and negative effects associated with non-medical use 
of MPH; (3) description of ethical, social, and legal issues associated with non-
medical use of MPH and (4) recommendations for the prevention of the non-
medical use of MPH. Coding of the ethical, legal and social content was 
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furthered by determining if the coded statements affirmed, negated, or remained 
neutral or ambivalent regarding the issue at stake.   
Given our goal of examining different ethical, social and legal issues 
surrounding the non-medical use of MPH, we used basic descriptive statistics to 
report the frequency and distribution of various codes. Data is reported to 
illustrate the nature of statements found within discourses and contrast 
discourses on the non-medical use of MPH. 
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Table 5-2: Coding structure used to analyze media, bioethics, and public health 
discourses on the non-medical use of methylphenidate (MPH) 
Section 1: Description of non-medical use of MPH 
1.1. Definitions and synonyms for non-medical use of MPH 
 Formal definition of non-medical use of MPH 
 Lay descriptions of non-medical use of MPH 
 Distinction between treatment and enhancement 
1.2. Uses of MPH 
 Medical use 
 Cognitive and academic performance enhancement use 
 Recreational use 
1.3. Aims of non-medical use of MPH 
1.4. Extent of non-medical use of MPH 
Accepted 
Frequent 
Neutral 
Questionable 
 
Rare 
1.5. Description of practices of non-medical use of MPH 
 When is MPH used non-medically 
 Who is using MPH non-medically 
 Where is MPH used non-medically 
 How MPH is procured for non-medical use 
 Black market 
 Buying pills from other students 
 Feigning symptoms of ADHD 
 Online pharmacies 
 Other 
1.6. Types of non-medical use of MPH reported 
 Methylphenidate 
 Other neuropharmaceuticals 
 Non neuropharmaceutical 
 Other 
Section 2: Workings and effects of MPH 
2.1. How MPH works 
2.2. Physiological effects of non-medical use of MPH 
 Physiological negative effects of non-medical use of MPH 
 Physiological positive effects of non-medical use of MPH 
2.3. Psychological effects of non-medical use of MPH 
 Psychological negative effects of non-medical use of MPH 
 Psychological positive effects of non-medical use of MPH 
2.4. Unknown effects of non-medical use of MPH 
2.5. Information on ADHD 
 Nature of ADHD 
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 Prevalence of ADHD 
Section 3: Ethical, social and legal issues associated with non-medical use of MPH * 
3.1. Abuse 
3.2. Authenticity, identity, and personhood 
3.3. Autonomy, individual rights, and informed consent 
3.4. Cheating 
3.5. Commercialization 
3.6. Illegality 
3.7. Injustice, access, and equality 
3.8. Overprescription 
3.9. Regulation and governance 
3.10. Reliability of scientific research 
3.11. Safety  
3.12. Social meaning 
3.13. Social integration and acceptability  
Section 4: Prevention of non-medical use of MPH and related challenges 
4.1 Solutions 
4.2 Challenges 
*Content under these codes was further analyzed into 3 coding options: (1) 
affirmation of the issue; (2) negation of the issue; (3) neutral or ambivalent stance 
regarding the issue with the exception of ‘Regulation and governance’ whose content 
was not suited for this kind of analysis and presented with recommendations for 
prevention. 
 
 
Results 
Portrayal of non-medical uses of MPH 
 
We first examined how the non-medical use of MPH for performance 
enhancement was portrayed in the media in comparison to scholarly bioethics 
and public health discourses. We found that a wide-array of terms was used in 
the print media, many of which conferred a sense of familiarity and efficacy 
(e.g., “study aid”, “study tool”) regarding this form of MPH use (Box 5-1). In 
the media, typical statements regarding the non-medical use of MPH for 
performance enhancement described it as a lifestyle choice or a form of illicit 
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street drug (e.g., “better living through chemistry”) while the formal term of 
“cognitive enhancement” was found almost exclusively in bioethics discourse. 
Public health discourse negatively described this practice as a form of illicit 
prescription drug misuse or abuse (Table 5-3). In addition to the reported non-
medical uses for performance enhancement (20 PM; 14 B; 7 PH), which was a 
selection criteria, other uses of MPH were generally discussed including 
medical uses to treat AD/HD (16 PM; 5 B; 5 PH) and recreational uses (6 PM; 
1 B; 7 PH).  
The headlines used to present the articles reflected the diverging views 
found in print media, bioethics and public health discourses (see again Table 5-
3). Features of print media headlines included presenting the non-medical use 
of MPH in the present tense as a current practice (N=16/23); describing MPH 
as a study aid (N=10/23); featuring cautionary messages (N=9/23); mentioning 
that this is a new or more prevalent practice (N=8/23); describing this practice 
as a form of abuse (N=7/23). Bioethics headlines typically described non-
medical neuropharmaceutical use as “enhancement” (N=8/14) and public health 
papers as a form of abuse or misuse (N=7/7). The term cognitive enhancement 
was seldom encountered in print media and never in public health discourse. In 
terms of risk and benefit statements, the risk of addiction was present in all 
discourses while the print media presented a wider array of risks. In comparison 
to the prescribing information provided by Novartis (Ritalin®, Novartis 
Pharmaceuticals Corp., East Hanover, NJ, USA; Dorval, Québec, Canada; 
Frimley/Camberley, Surrey, UK; North Ryde, NSW, Australia) for MPH in the 
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US, Canada, UK, and Australia (where the articles originated), most of these 
risks were common risks and few of the uncommon and rare side effects were 
featured.    
Box 5-1: Lay designations of methylphenidate used non-medically 
for performance enhancement in the print media* 
 
“study aid” [35] (9) 
“brain steroid” [26] (4) 
“smart drug(s)” [45] (4) 
“Vitamin R” [35] (4) 
“poor man’s cocaine” [2] (3) 
“study tool(s)” [26] (2) 
“new chemical aid” [26](1) 
“smart pill(s)” [20] (1) 
 “cramming drug” [15] (1) 
“wonder drug” [42] (2) 
 “academic steroids” [35] (1) 
“steroids of academia” [33] (1) 
 “legal speed” [28] (1) 
“kiddie speed” [27] (1) 
*Number of occurrences of specific 
designations indicated in parentheses 
 
Analyzed articles typically described: (1) who is using MPH non-
medically (e.g. college students; 18 PM; 8 B; 6 PH); (2) when MPH is used 
non-medically (e.g., during final exams; 13 PM; 0 B; 3 PH); (3) where MPH is 
used non-medically (e.g., college campuses and high schools; 11 PM; 5 B; 4 
PH). Details were also reported, notably in print media, on how students were 
securing MPH for non-medical uses, i.e., by buying pills from other students 
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(14 PM; 1 B; 3 PH); by feigning symptoms of ADHD (5 PM; 0 B; 2 PH); 
through black markets (5 PM; 0 B; 1 PH); through Internet pharmacies (4 PM; 
0 B; 0 PH) and by stealing pills (3 PM; 0 B; 1 PH). Medical information on 
what ADHD is (3 PM; 2 B; 0 PH) and information on ADHD such as statistics 
on occurrence (3 PM; 1 B; 1 PH) were generally rare. 
The extent and social acceptance of non-medical uses of MPH was 
described in divergent ways particularly in the print media (PM). We found  
contrasting statements that this practice was: (1) “accepted” (6 PM; 0 B; 1 PH); 
(2) “frequent” and “widespread” (16 PM; 8 B; 5 PH); (3) the subject of 
ambivalent opinions (6 PM; 0 B; 0 PH); (4) “debatable” and “concerning” (10 
PM; 1 B; 3 PH); and  (5) rare and anecdotal (6 PM; 0 B; 0 PH).  
Given its focus on enhancement, it was not surprising to find that the 
bioethics literature in particular featured alternate forms of performance 
enhancement rather than solely the use of MPH (20 PM; 14 B; 7 PH). The 
bioethics literature discussed enhancement by means of other pharmaceuticals 
(0 PM; 8 B; 0 PH); traditional forms of enhancement such as caffeine and 
nutritional supplements (1 PM; 6 B; 0 PH) as well as other forms of 
enhancement (e.g., transcranial magnetic stimulation (0 PM; 4 B; 1 PH). 
Further, bioethics discourse alluded to the treatment-enhancement dichotomy, 
often judged to be blurry or misleading (2 PM; 9 B; 0 PH) to understand the 
implications of non-medical use of MPH. 
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Table 5-3: Portrayal of the non-medical use of methylphenidate in print media, bioethics and public health supported by examples of article headlines as well 
the occurrence of reported risks and benefits indicated in parentheses (n). 
Portrayal as a “Lifestyle choice”: “better living through chemistry” [54]; “short cut in learning”; “new kind of drug abuse” [26]. 
Examples of headlines: “Students taking danger drug to help with exams”; “‘Smart pills’ are on the rise. But is taking them wise?”; “New campus 
high: Illicit prescription drugs”. 
Reported risks*: Physiological addiction (8); palpitations (7); psychological addiction (6); heart attack (5); unspecified cardiac risks (4); loss of 
appetite (4); hallucinations (4); stroke (2); tremors (2); increase in blood pressure (2); weight loss (2); vomiting (2); dizziness (2); seizures (2); 
withdrawal symptoms (2); require increasing amounts of drug (1); cardiac arrhythmia (1); overdose (1); changes in brain cell chemistry (1); fatigue 
(1); death (1); dry mouth (1). 
P
r
i
n
t
 
m
e
d
i
a
 
Reported benefits**: Boost concentration (8); increase focus (7); increase energy (3); increase alertness (1); reduce appetite (1); eliminate jitters (1); 
filter out distractions (1); increase motivation (1); accumulate more information in less time (1); increase confidence (1); increase organization (1); 
increase retention of information (1); think more rationally (1); general feeling of well-being (1); make you feel smarter (1); make mundane tasks seem 
fun (1); enhance studying (1); do work faster (1); maintain high performance level (1); boost brain activity (1). 
Portrayal as “Cognitive enhancement”: “ ‘neuroenhancement’ (…) This term includes the use of drugs and other interventions to modify brain 
processes with the aim of enhancing memory, mood and attention in people who are not impaired by illness or disorder” [23]. 
Examples of headlines: “Neurocognitive enhancement: what can we do and what should we do?” and “Cosmetic neurology: The controversy over 
enhancing movement, mentation, and mood”.   
Reported risks*: Addiction (3); toxicity (1). 
B
i
o
e
t
h
i
c
s
 
Reported benefits**: Improve attention (4); improve memory (4); improve performance (2); increase focus (1); improve concentration (1); improve 
planning (1); think faster (1); stabilize mood (1); promote creativity (1). 
Portrayal as “Abuse”, “misuse”, “illicit drug use”: “Ritalin (Novartis Pharmaceuticals Corp., East Hanover, NJ) has received the most attention in 
medical literature, little information is available regarding which specific stimulants are used illicitly by college students” [48]. 
Examples of headlines: “Student perceptions of methylphenidate abuse at a public liberal arts college” and “Stimulant medication use, misuse, and 
abuse in an undergraduate and graduate student sample”. 
Reported risks*: Addiction (2); cardiovascular implications (1); withdrawal symptoms (1); increase in blood pressure (1); headache (1); overdose (1); 
blocking veins if injected/snorted (1); panic episodes (1); aggressive behavior (1); suicidal or homicidal tendencies (1). 
P
u
b
l
i
c
 
h
e
a
l
t
h
 
Reported benefits**: Decreases fatigue (2); increases energy (1); increases dopaminergic activity (1); maintain high performance level (1); increase 
alertness (1). 
*Coded as physiological/psychological negative effects **Coded as physiological/psychological positive effects
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Ethical, legal and social issues of non-medical use of MPH 
There were generally wide-ranging views on the ethical, legal, and 
social issues related to the non-medical use of MPH. Table 5-4 provides a 
comprehensive summary of the issues identified and their diverse 
interpretations (column 1) as well as illustrative examples of statements 
(column 2). For most issues, both statements that an issue was important and 
rebuttal statements could be found across discourses. One notable exception 
was the issue of overprescription of MPH, which seemed to be affirmed by all 
discourses and only negated once. Bioethics discourse was comprehensive in its 
coverage of ethical and social issues. However, some issues were not discussed 
in our sample of print media and public health discourses. These are 
authenticity, identity and personhood; autonomy, individual choice and 
informed consent; injustice and inequalities. Our study design did not allow 
assessment of the ratio of arguments but we can observe that some issues 
appeared to be more commonly negated in bioethics discourse (e.g., 
authenticity, identity and personhood; autonomy, individual choice and 
informed consent), see sections 2 and 3 of Table 5-4 for examples. 
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Table 5-4: Frequency, distribution, characterization and representative 
examples of ethical, social and legal issues associated with the non-medical use 
of methylphenidate (MPH) for performance enhancement in print media (PM), 
bioethics (B) and public health (PH) discourses. 
Frequency, distribution and 
characterization of ethical, social, 
and legal issues (Frequency in PM, 
B, PH indicated in parentheses) 
Representative examples of ethical, 
social, and legal issues 
1. Abuse 
Affirmation (11, 1, 5): MPH is a 
drug with high abuse potential (PM, 
PH). Diversion of MPH to healthy 
people for cognitive enhancement 
can be considered an abuse or 
misuse of the drug though there is 
confusion as to which one it is (PM, 
PH). This use of MPH is analogous 
to abuse of illicit drugs (B, PH). 
“ ‘There is no question Ritalin is being 
misused by college students,’ Shaw 
said”. (PM)[15] 
“Despite its wide margin of safety, 
MPH is thought to have high abuse 
potential.” (PH)[4] 
Negation (1, 1, 1): The use of MPH 
for cognitive enhancement is not an 
abuse of the prescription; it is a 
study tool (PM, B, PH). 
“Moreover, the government would have 
difficulty maintaining that enhancing 
cognition was an abuse, especially given 
the legality of caffeine and nicotine.” 
(B) [31] 
“The majority of students who reported 
misuse or abuse were not concerned 
about the misuse and abuse of 
prescription stimulants, and a number of 
students thought that they should be 
more readily available.” (PH) [49] 
2. Authenticity, identity and personhood 
Affirmation (0, 5, 0): Cognition 
enhanced by MPH is authentic and 
belongs to the person (B). 
“And if we are not the same person on 
Ritalin as off, neither are we the same 
person after a glass of wine as before, or 
on vacation as before an exam.” (B) 
[18] 
Negation (1, 12, 0): By using MPH 
for cognitive enhancement, 
individuals are being deceptive 
about their abilities and cheapen the 
value of life experience (PM, B). 
“ ‘I think it’s deceptive. A GPA is what 
employers and graduate schools use to 
select students. It is supposed to be 
indicative of your natural academic 
ability,’ said Ramin Baghai, 25, a 
master's of business administration 
student at Massachusetts Institute of 
Technology.” (PM) [25] 
3. Autonomy, individual choice and informed consent 
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Affirmation (0, 5, 0): The choice 
whether to enhance cognition with 
MPH (or not) is a matter of 
individual liberty (B). 
“In a culture with strong libertarian 
undercurrents, many believe that if 
individuals are given adequate 
information about potential side effects, 
they should be free to make their own 
decisions.” (B) [12] 
Negation (0, 10, 0): Individuals may 
feel coerced into enhancing their 
cognition with MPH because of 
social pressure to do so or they may 
feel that their individual liberty is 
stifled by a ban (B). 
“Use by some people will result in 
pressure on nonusers to become users, 
or else to accept what amounts to a 
handicap in the social competition.” (B) 
[50] 
4. Cheating 
Affirmation (5, 8, 0): Using MPH for 
cognitive enhancement creates an 
unfair playing field and thus can be 
regarded as cheating (PM, B). It is a  
quick fix for hard work and 
contributes to the medicalization of 
human effort (B). 
“Some students who don’t use the drug 
say their pill-popping classmates have 
an unfair edge and consider use of the 
pills a form of cheating.” (PM) [25] 
“The academic or professional 
milestones attained by those with 
biotechnologically-enhanced cognition 
may be tainted, affecting the 
individual’s sense of achievement.”  (B) 
[8] 
Negation (3, 3, 0): Using MPH for 
cognitive enhancement is no more 
unfair than hiring private tutors and 
using other technologies that help 
cognition (PM, B). Cognitive 
enhancement can accelerate or 
optimize a task but is not a substitute 
for the work involved (B). 
“You deserve to win a Nobel Prize if 
you discover the cure for cancer, 
whether or not you do so with the aid of 
cognitive enhancement drugs.” (B) [31] 
5. Commercialization 
Affirmation (1, 7, 0): There are 
economic motivations encouraging 
non-medical use of cognitive 
enhancers (PM, B). 
“Today, the possibilities of 
pharmacological enhancement and 
lifestyle-related use are multiplied in 
conjunction with the intensification of 
marketing by pharmaceutical 
companies.” (B) [40] 
Negation (0, 1, 0): Interests of 
pharmaceutical companies are not 
part of the debate of whether there is 
something wrong with enhancement 
(B). 
“Pharmaceutical companies may be evil 
incarnate. And we may be putty in their 
pecuniary little hands. But that has 
nothing at all to do with the question of 
whether there is anything wrong with 
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 pursuing enhancement.” (B) [11] 
6. Illegality 
Affirmation (8, 2, 0): There are legal 
issues associated with the possession 
and consumption of MPH for 
cognitive enhancement (PM, B). 
“And since the drug is classified as a 
controlled substance, possessing or 
distributing it without a doctor’s 
prescription is a felony.” (PM) [42] 
“Some worry that tomorrow’s lawyers, 
doctors and business professionals are 
committing felonies before they have 
even begun practice.” (PM) [31] 
 
Negation (3, 1, 0): MPH is a legal 
drug and can be used for cognitive 
enhancement (PM, B). 
“So where people once took illegal 
drugs like cocaine to escape or stimulate 
creativity, they now take legal drugs to 
focus better and achieve more.” (PM) 
[54] 
“But as noted earlier, cognitive 
enhancement drugs may be perfectly 
legal (because they are dietary 
supplements, have FDA approval for an 
enhancement indication, or are 
prescribed for off-label use).” (B) [31] 
7. Injustice and inequalities 
Affirmation (0, 10, 0): Unequal 
access to MPH for cognitive 
enhancement exacerbates 
inequalities between social groups 
e.g. rich/poor, insured/uninsured (B).
“The entire population would move 
upward in terms of cognitive ability, but 
the disparities created by natural talent 
and luck would remain.” (B) [31] 
“Moreover, most Americans would 
probably agree that the financial burden 
associated with enhancement procedures 
should not be distributed - through 
increased insurance premiums or 
allocation of limited federal resources - 
among members of society.” (B)[8] 
Negation (0, 6, 0): Fear of creating 
or amplifying social inequalities is 
not a valid ground for prohibiting 
cognitive enhancement with MPH as 
society already tolerates other social 
injustices such as public versus 
private schools (B). 
“Unequal access is generally not 
grounds for prohibiting neurocognitive 
enhancement, any more than it is 
grounds for prohibiting other types of 
enhancement, such as private tutoring or 
cosmetic surgery that are enjoyed 
mainly by the wealthy.” (B) [18] 
8. Overprescription 
Affirmation (9, 2, 4): MPH has been “Heiligenstein says that the fact that 
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overprescribed in recent years. High 
rates of prescription contribute to the 
abuse/misuse of MPH (PM, B, PH). 
students are giving away supplies means
they didn’t need them in the first place 
or, at least, not in the dosages 
prescribed.” (PM) [35] 
“There has been a trend in the increased 
abuse and misuse of stimulant 
medications by students, which likely, 
as suggested by others, has been 
influenced by increased production of 
and prescriptions written for stimulant 
medications, particularly 
methylphenidate.” (PH) [49] 
Negation (1, 0, 0): MPH is not 
overprescribed; ADHD is being 
recognized and treated more readily 
(PM). 
“Dr. Lenard Adler doesn’t think it’s a 
problem. Medco’s report ‘highlights that 
we’re starting to do a better job of 
heightening recognition of adult ADHD 
and more individuals are coming in to 
get treated, but undertreatment is still 
vastly more of a problem as compared 
to overtreatment,’ says Adler, the 
director of the Adult ADHD program at 
NYU.” (PM) [28] 
9. Reliability of scientific research 
Affirmation (0, 0, 0): None N/A 
Negation (2, 4, 1): MPH’s long-term 
safety and effect on normal 
cognition remain to be scientifically 
proven so judgments about whether 
the practice is permissible cannot be 
made (PM, B, PH). 
“There is therefore no a priori reason — 
irrespective of ethical concerns or any 
other arguments — to suppose that, in 
the absence of pathology, 
pharmacological enhancement of such 
processes will necessarily enhance 
memory or cognition, which might 
already be ‘set’ at psychologically 
optimal levels.” (B) [43] 
“Stimulant medications are intended to 
improve academic performance, 
although studies have not shown long-
term academic benefits from their use.” 
(PH) [22] 
10. Safety 
Affirmation (3, 2, 2): MPH is a safe 
drug or is viewed as safe because it 
has been officially approved and its 
side effects are minimal (PM, B, 
PH).   
“Heiligenstein says that part of the 
problem is a perception that prescription 
drugs, as opposed to “street” drugs, are 
safe because they have been officially 
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approved.” (PM) [35] 
“And most of the drugs we’re talking 
about are far less harmful than 
nicotine.” (PM) [54] 
Negation (2, 11, 2): MPH is a 
prescription drug and may reveal 
previously unanticipated side effects 
if used outside of a prescription 
(PM, B, PH). 
“Brain-based enhancement involves 
intervening in a complex and poorly 
understood system, and the likelihood of 
unanticipated problems is consequently 
higher.” (B) [17] 
“Although prescribed use of 
methylphenidate appears to be relatively 
safe, misuse or abuse of any stimulant 
medication can have adverse, if not 
deadly, consequences.” (PH) [49] 
11. Social meaning 
Affirmation (11, 9, 5): The non-
medical use of MPH is a response to 
the pressure of a competitive society 
(PM, B, PH).  The non-medical use 
of MPH is changing society’s values 
by prizing achievement over hard 
work (PM, B). People will not learn 
how to cope with problems but 
rather seek quick fixes (PM). It 
could make society more efficient 
and productive if everyone was 
enhanced (B). It is a public health 
problem (PH). 
“Ritalin acts as a quick fix for problems 
that are the product of the rapid-fire 
culture and the hurried society in which 
we live.” (PM) [5]  
Negation (1, 2, 0): Students have 
always used stimulants to help them 
perform; this practice is no different 
(PM). Only the result counts (B). 
“Short of misappropriating someone 
else’s work, the value of the results is 
what counts. Nor is this an objectionable 
case of the ends justifying the means; no 
harm is produced by exceptional ability 
or serendipitous discovery, except 
perhaps envy, which arguably is 
generated by any achievement, 
including one that is earned by hard 
work.” (B) [31] 
12. Social integration and acceptability 
Affirmation (11, 13, 0): Misuse of 
MPH has changed social practices 
becoming a “fact of life” (PM, B). 
Enhancement using MPH is 
considered as trivial as a more 
“Ritalin makes repetitive, boring tasks 
like cleaning your room seem fun,” said 
Josh Koenig, a 20-year-old drama 
major. “I equate it in my mind with a 
really strong cup of coffee.” (PM) [53] 
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“traditional” method like coffee 
(PM). Enhancement is a very old 
social practice (e.g. coffee and 
alcohol) and the use of 
psychopharmacology is only a new 
form (B). 
 
Negation (5, 0, 0): Misuse of MPH 
has not changed social practices that 
already permit individuals to 
practice enhancement by other 
means. MPH is not any more 
dangerous than these other methods. 
Use of MPH for enhancement is 
regarded as progress (PM). 
“No one’s going to say ‘Don’t smoke 
cigarettes before the SAT.’” (PM)  [54] 
*All descriptions are based on a summary of content found in discourses 
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Recommendations for prevention of non-medical use of MPH and related 
challenges 
 
A wide range of solutions were proposed to prevent further non-medical 
use of MPH (Table 5-5). Bioethics discourse called for restrictive legislation on 
MPH and other potential performance enhancing drugs in healthy people by 
criminalizing non-approved uses. However, opposing recommendations, such 
as favorably legislating these drugs (e.g., government subsidies for those who 
cannot afford the drugs) were presented. The print media and public health 
discourses, on the other hand, promoted changing the habits of healthcare 
professionals in diagnosis and prescription compliance and also informing 
students and university staff about the misuse of prescription drugs and its risks.  
Several challenges were highlighted regarding the prevention of non-
medical use of MPH (Table 5-5). These included the logistical complexity and 
legitimacy of enforcing a ban and the detrimental impact of a ban on patients 
who need the drugs to function. The most emphasized challenge was the sense 
of security that individuals have with regard to prescription drugs, i.e., even 
non-medical uses because they are approved by a governmental health agency.
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Table 5-5: Proposed recommendations to prevent non-medical use of methylphenidate (MPH) and challenges associated with prevention. 
A. Proposed recommendations to prevent non-medical use of MPH 
Print media Bioethics Public health 
Diagnosing ADHD more carefully [24, 35, 42] 
Supervising of students with stimulant 
prescriptions[2, 25] 
Teaching students effective study skills and stress 
management [5, 35] 
Informing students and staff of the dangers of 
abusing prescription drugs [2, 15, 25, 26] 
Criminalizing non-approved uses of medications 
[18, 31, 50] 
Prohibiting prescription of drugs for lifestyle 
purposes by doctors  [31] 
Obliging manufacturers to declare safety data for 
unapproved uses to the FDA [31] 
Subsidizing cognition enhancing drugs to allow 
equal access [23, 31] 
Establishing a “ceiling” as the maximum cognitive 
enhancement permissible [31, 50] 
Ensuring prescription compliance 
and responsible prescription 
practices [4, 49] 
Prescribing preparations that are 
less easily abused [46, 47] 
Identifying persons who are liable 
to abuse medication [4] 
Educating healthcare providers 
dealing with university populations 
as to the abuse potential of 
stimulants [47, 49] 
B. Identified challenges in the prevention of non-medical use of MPH 
Print media Bioethics Public health 
Logistical problems of enforcing a ban. [1, 35, 42] 
Perceived safety of MPH makes convincing students 
about its dangers more difficult [20, 35] 
Abundance  of MPH in healthcare system [24] 
Misuse of MPH bypasses traditional sources of 
information on indications and risks when taking a 
prescription medication [35] 
Difficult to propose a ban on cognitive enhancers 
because of their routine use in treatment [23, 31, 
50] 
Ban is liable to encourage a black market and be 
just as coercive as social pressure [23, 31, 50] 
FDA has little experience in assessing social 
cost/benefit of a drug and thus is unfit to take 
charge of such regulation [50] 
None identified 
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Discussion 
This study examined discourses on the non-medical use of MPH by college 
students in the print media, bioethics literature, and public health literature. We 
found that there were three distinct paradigms used to describe the non-medical 
use of MPH: the “lifestyle paradigm” in the print media; the “cognitive 
enhancement paradigm” in bioethics; and the “prescription drug abuse 
paradigm” in the public health literature. These paradigms were reflected 
notably in the headline content across discourses and the statements used to 
describe the non-medical use of MPH (Table 5-3). The lifestyle paradigm is 
also well illustrated in the print media’s use of lay designations to describe the 
non-medical use of MPH (Box 5-1) and the enthusiastic terms used to describe 
its potential enhancement effects (Table 5-3). We observed diverging claims 
about the frequency and acceptability of non-medical MPH use. The print 
media provided overall detailed descriptions of who, where, and when MPH 
was used non-medically and also how students were procuring it. The ethical 
discussion surrounding the non-medical use of MPH was without surprise more 
comprehensive in the bioethics literature but overall showed signs of 
fundamental ambivalence except in the public health literature where there was 
a clear stand against non-medical uses of MPH. Recommendations ranging 
from calls for legislation to increased public education were identified in all 
three sources of discourse but challenges were only identified and discussed in 
the print media and in the bioethics literature.  
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Limitations 
As with most qualitative research, some aspects of our study limit the 
generalization of the results. First, the small sample size and limited sample 
composition, in spite of broad searches and use of multiple databases, are not 
exhaustive of all discourses on non-medical use of MPH. The results of this 
small study should accordingly be viewed a preliminary step to fulfill this goal. 
Second, the scope of the study was limited to a few countries, mostly because 
of the available sources of the literature. Third, the specific case of the misuse 
of MPH was examined even though there are other drugs that are misused in 
similar ways. However, this choice is supported by the apparent draw of MPH 
for performance enhancement as reported in a recent survey published in 
Nature [29]. Fourth, the reported statements in the print media articles are an 
amalgamation of opinions from people interviewed by journalists and do not 
necessarily reflect the opinions of journalists. Accordingly, the print media 
content should be viewed as what was available to the public through this 
channel rather than the voice of journalists per se. 
 
Disagreements between paradigms could have important healthcare, ethics, and 
social implications and consequences 
  
The dissonance we observed between paradigms used to describe and 
evaluate the non-medical use of MPH for performance enhancement could have 
profound healthcare, ethics and social implications and consequences. Each 
paradigm carries forward a distinct view of the acceptability of MPH non-
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medical use. Speaking of a “lifestyle choice”, a “cognitive enhancement”, or a 
“prescription misuse” matters for scholarly biomedical ethics as well as for 
public debate and healthcare. Another major source of disagreement is the 
unbalanced presentation of the potential positive and negative effects of MPH 
across discourses. In the print media especially, a great number of potential 
adverse effects (Table 5-3) are mentioned most often without qualification or 
quantification. In contrast to the risks, the positive effects are discussed using 
sensational terms like “wonder drug” or “smart drug” (Box 5-1). Such 
discourse implies miracle-like effects and portrays the practice in a light that 
does not reflect our limited scientific and medical knowledge of the effects of 
non-medical MPH use [6]. Furthermore, the reported positive effects in the 
print media are largely based on anecdotes and are typically not contrasted with 
scientific data about the effects of MPH on the healthy brain. Given these 
features, some interpretations found in print media as well as bioethics 
discourse could contribute to the unintended dissemination of the non-medical 
use of MPH for performance enhancement.  However, if public health 
discourses prematurely condemn this practice as a form of drug abuse, future 
public health strategies risk being ill-equipped to tackle the enthusiasm and 
interest for cognitive enhancers found in other discourses. The divergences 
underpinning the three paradigms we identified show the lack of consensus on 
the non-medical prescription drug use. Likewise, ethical statements, especially 
in the print media are often ambivalent making it difficult for the public to 
assess the implications of this practice.  
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Bioethics and the print media could reinvigorate their commitment to public 
information and informed debate 
 
Bioethics discourse and, to some extent, the print media, contain 
discussions on the ethics of the non-medical use of MPH. Our results show, that 
the coverage of the phenomenon in these discourses brings about potential 
sources of confusion. For instance, there is a wide range of uncertain claims 
about the prevalence and risks of the practice. The bioethics literature is also 
marked by the enhancement paradigm it employs. The term “cognitive 
enhancement” implies that using MPH non-medically is indeed effective and 
yields a beneficial enhancement (in contrast to the prescription drug abuse 
paradigm).  
The print media conveys in many respect more sociological details and 
context (e.g., who, how, when and where) regarding the non-medical use of 
MPH for performance enhancement. However, this may have unexpected 
consequences such as increasing the prevalence of the practice. In fact, the 
combination of consumption details and student testimonials with positive 
portrayals of the performance enhancement potential of MPH in the print media 
may incite individuals to engage in the practice. Even though the social and 
ethical context of performance enhancement with MPH differs in many 
respects from those of illicit drug abuse (drug addiction) it is interesting to 
compare discussions on these two phenomena. For example, the Australian 
Press Council has produced guidelines that go as far as recommending 
avoidance of reporting “stories that might excite the interest of young people in 
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drug experimentation, including the naming of dangerous drugs”. The 
recommendations for reporting on addictive drugs also state that “the harmful 
effects of any particular drug should not be exaggerated or minimized”; and that 
we should “avoid detailed accounts of consumption methods, even though 
many young people are generally familiar with them.” The recommendations 
also “guard against any reporting which might encourage readers’ 
experimentation with a drug, for example highlighting the ‘glamour’ of the 
dangers involved” [13]. 
There are potentially some important lessons about reporting on non-
medical uses of MPH and other pharmaceuticals that can be gleaned from the 
guidelines put forth by the Australian Press Council. The guidelines urge 
responsible reporting in ways that clearly contrast with the glamour conveyed 
about cognitive enhancers, the detailed consumption accounts, and the 
debatable reporting of potential benefits and risks. Though the case of using 
neuropharmaceuticals to enhance cognitive performance is clearly not the same 
as illicit drug abuse, these guidelines could translate into avoidance of 
narratives and salient practices related to non-medical MPH by students as well 
as other forms of non-medical use of prescription drugs. This represents a 
strong stance that could appear paternalistic and an interference with good 
reporting practices but the onus of responsible reporting does not lie exclusively 
upon journalists. All stakeholders need to consider their role and 
responsibilities in the construction of news about non-medical uses of 
pharmaceuticals for performance enhancement. For instance, healthcare 
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providers being interviewed on this topic may want to be vigilant about the 
opinions they express to journalists about non-medical practices especially 
regarding risks and benefits. For example, a clinical psychiatrist was quoted as 
saying that “Caffeine is fine. This is better (…) Students are able to accumulate 
more information in a shorter time frame. These drugs keep you awake longer. 
They minimize fatigue and help maintain a high performance level” [25]. Drug 
companies are prohibited from marketing off-label uses of their medications. 
Perhaps healthcare professionals should be careful with their public comments 
on non-medical uses of pharmaceuticals. Public health agencies must also be 
aware of enthusiastic media reports on practices potentially having an impact 
on public health if they want to counterbalance unwarranted messages in the 
media and better inform the public and stakeholders. These are some initial 
venues to explore to improve the commitment to public information and 
informed debate on non-medical uses of prescription drugs for enhancement 
purposes.  
Medicine, healthcare, and society need to prepare for broader and more 
prevalent non medical uses of pharmaceuticals 
 
In our study, public health discourses on enhancement raised many 
concerns about the non-medical use of MPH for performance improvement 
because of its potential health consequences. The prevalence of this practice 
with MPH, which ranges from 3.2% [47] to 11% [49], is concerning since it 
involves use of a controlled substance by individuals outside of the intended 
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clinical context. This trend has the potential to prepare the path for the general 
acceptability of non-medical uses of pharmaceuticals. Accordingly, societies 
could be faced with serious public health challenges before the ethics of this 
practice is properly discerned and publicly debated. We did note that wide 
ranging solutions were suggested to prevent the expansion of the non-medical 
use of MPH for enhancement purposes (Table 5-5). Development of legislation 
on non-medical uses and distribution of prescription medications were common 
suggestions as well as the education of healthcare professionals and the public 
about the dangers of misusing prescriptions. The latter recommendations mirror 
those put forth recently to tackle the widespread illegal provision of human 
growth hormone (hGh) in the US [34]. These recommendations focus mostly 
on the illegal distribution of hGh by manufacturers but also highlight the ethical 
responsibilities of healthcare professionals. Though the stakeholders in 
cognitive enhancement with neuropharmaceuticals are different than in hGh, 
there appears to be similar problems with fraudulent distribution online and 
trafficking of MPH among students [29, 35]. Prevention of these kinds of 
distribution, stricter prescription practices, better patient prescription 
compliance and effective, balanced information to the public could help 
decrease prevalence and social integration of the practice in the absence of 
medical, social, and ethical consensus about its acceptability. Regulatory bodies 
and policy makers could begin examining the hGh recommendations as well as 
their associated challenges to model potential action with regard to the 
emerging practice of the non-medical use of MPH. However, before any new 
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policies are made there clearly needs to be a broader debate on the non-medical 
uses of neuropharmaceuticals in order to sort through the ambivalence with 
regard to ethical and social issues. 
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This thesis examined discourses on ethics and public understanding 
related to the cognitive enhancement of healthy individuals with 
neuropharmaceuticals. This was examined using the specific example of 
cognitive enhancement with methylphenidate in healthy university students. 
Recent studies have reported that the use of methylphenidate for performance 
enhancement is prevalent in North American university campuses and is 
beginning to spread to professional environments as well.  The example of non-
medical methylphenidate use for cognitive enhancement has been discussed in 
both lay and academic discourses providing some material for comparison of 
perspectives.  
Chapter 3 provided a brief look at the emergence and ethics of cognitive 
enhancement. Given important issues like safety, fairness, distributive justice 
and the social integration of cognitive enhancement, this article suggested broad 
social discussion to encourage thinking about future policy.  
Chapter 4 presented observations on how the phenomenon was 
portrayed in different discourses. The content of lay and academic discourses 
on the non-medical use of methylphenidate for cognitive enhancement was 
examined to characterize its portrayal. We found evidence of three distinct 
paradigms that describe the non-medical use of methylphenidate for cognitive 
enhancement: the “lifestyle paradigm” in the print media; the “cognitive 
enhancement paradigm” in bioethics; and the “prescription drug abuse 
paradigm” in the public health literature.  
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Chapter 5 expanded upon the observations of Chapter 4 by further 
analyzing the differences in discourses on the non-medical use of 
methylphenidate by college students for cognitive enhancement present in the 
print media, bioethics literature, and public health literature. The results of this 
discourse analysis showed that there are important differences in perspectives. 
The print media used lay designations to describe the non-medical use of 
methylphenidate (e.g., smart pill) and enthusiastic terms used to describe its 
potential enhancement effects (e.g., wonder drug). Our discourse analysis 
revealed diverging claims about the frequency and acceptability of non-medical 
methylphenidate use. The print media provided overall detailed descriptions of 
who, where, and when methylphenidate was used non-medically and also how 
students were procuring methylphenidate for such uses. The ethical discussion 
surrounding the non-medical use of methylphenidate was most comprehensive 
in the bioethics literature. Overall, we found signs of ambivalence regarding 
issues like the fairness and justice of cognitive enhancement. In contrast, there 
was a clear stand against non-medical uses of methylphenidate in the public 
health literature. Recommendations ranging from calls for legislation to 
increased public education were identified in all three sources of discourse but 
challenges were only identified and discussed in the print media and in the 
bioethics literature.  
The results of this thesis bring to the forefront a number of themes that 
merit further discussion. One of our key findings was that there are gaps 
between different paradigms regarding the future of non-medical uses of 
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neuropharmaceuticals for cognitive enhancement. These discrepancies can 
create ethics “blind spots” with important ethical consequences. Any of these 
discourses taken individually provides an incomplete perspective of cognitive 
enhancement making a comprehensive ethical analysis difficult. Another 
obstacle is the lack of agreement on fundamental aspects (e.g., the portrayal of 
cognitive enhancement, risks and benefits of the non-medical use of 
methylphenidate for cognitive enhancement and key ethical issues) which 
complicates interdisciplinary analysis. Most importantly, diverging discourses 
often ignore important topics. First, the history of neuropharmacology in 
psychiatry has shown the importance of social context in relation to 
neuropharmacology, the thorough investigation of efficacy and safety as well as 
the commercial interests that surround the use of neuropharmaceuticals.   
Second, given the potential for broad demand for cognitive enhancement, 
public health approaches need to be examined. Finally, potential avenues for 
future work on cognitive enhancement are proposed. Accordingly, this general 
discussion aims to address these four topics to set a basis for further reflection 
upon the non-medical use of neuropharmaceuticals for cognitive enhancement. 
Lessons for enhancement from the history of neuropharmacology 
Antecedent in use of neuropharmacology 
 Cognitive enhancement of healthy individuals has some roots in the 
development of pharmacological therapy in psychiatry. The use of substances 
to alter mental states is an old practice rooted in both medicine and cultural 
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tradition. For example, the effects of alcohol, opium and hemp are present in 
the historical accounts of many ancient cultures and may be viewed as crude 
forms of cognitive enhancement [129]. The use of drugs based on a biological 
understanding of mental illness is a fairly recent practice in psychiatry 
beginning in the mid 19th century with morphine for the treatment of neuralgic 
pain. Later, in the early 20th century barbiturates, more specifically 
phenobarbitol, were the all-purpose psychiatric drugs [12]. Up until the mid 20th 
century, psychiatrists were hesitant to use medication other than as a last resort 
[14]. However, in the 1950s, the discovery of an effective antipsychotic, 
chloropromazine (Thorazine), gave psychiatry its first blockbuster drug [14]. 
Establishing a link between the biological and the behavioral provided new 
avenues for treatment in psychiatry.  
The possibility to treat mental illness biologically set the tone for an 
increase in demand for psychiatric drugs and contributed to the interest in 
modifying mental states with neuropharmacology.  This can be illustrated by 
production and prescription of neuropharmaceuticals in recent years. For 
example, from 1990 to 2000 production of methylphenidate (Ritalin) increased 
nearly 900%. The production of amphetamines (Dexedrine and Adderall) 
increased 5 767% in the period between 1993 and 2001 [61]. The production of 
other neuropharmaceuticals experienced similar increases. Between 1993 and 
2001 the number of antidepressant prescriptions in the US rose 400% from 6.8 
million to 35.0 million [37]. In a profile of the consumption of prescription 
drugs in Québec, the Régie de l’assurance maladie du Québec (RAMQ) showed 
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that in 2000, 19.4% of individuals under 64 years old covered by the drug plan 
had prescriptions for drugs acting on the central nervous system [3]. The 2000 
percentage represents a 4.6% increase from 1998.  
As explained in Chapter 1, the treatment-enhancement distinction for 
some psychiatric conditions is not always clear since the divide between health 
and some common disorders can be blurry (e.g., depression and AD/HD). The 
burgeoning market for lifestyle drugs, as described in Chapter 1, encourages 
consumers to reach their potential with pharmaceuticals. This is not to say that 
there is a proven direct link between the rise of prescriptions and cognitive 
enhancement. However, one study uncovered that a high rate of diversion 
existed for stimulants used in the treatment of AD/HD [104] and many other 
types of prescription drugs are being diverted to black markets in Canada [60]. 
Thus, contextual factors like availability, desirability and market interests in 
lifestyle drugs may have begun to shape the landscape for a phenomenon like 
cognitive enhancement.   
The wider use of psychiatric drugs to treat mental illness brought 
neuropharmacology to new populations but also unveiled more of the risks 
associated with them. The subsequent popularity of psychiatric drugs such as 
the anti-anxiolitic meprobamate (Miltown) in the 1950s and 1960s, the anti-
depressant fluoxetine (Prozac) in the 1990s and the stimulant methylphenidate 
(Ritalin) in the 2000s brought neuropharmacology to a broader public. Yet with 
each breakthrough came debates about the continued use of these drugs. In the 
1970s meprobamate was thought to be addictive which lead to a US Senate 
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investigation on the addictive potential of benzodiazepines [144]. In the early 
1990s, research linked fluoxetine to suicidal thoughts in depressed patients 
causing a media backlash [72].   Intermittent debates, beginning in the late 
1980s, about the side effects of methylphenidate spurred several unsuccessful 
lawsuits and more media involvement [122]. The debate surrounding the risks 
of the medical use of methylphenidate in AD/HD is ongoing [46, 138].  These 
issues alerted the public to the risks associated with neuropharmacology but 
enthusiasm for it persisted despite findings about serious side effects like 
addiction. 
Importance of these lessons for cognitive enhancement 
History may be repeating itself in the case of cognitive enhancement of 
healthy individuals with neuropharmaceuticals. Our results indicate that using 
MPH for enhancement is already considered an integral part of social practice 
in some discourses. They also show that some media reports like the ones 
examined in Chapter 5 consider MPH comparable to “traditional” methods of 
enhancement that are acceptable such as consuming caffeine. Combined with 
praise of methylphenidate as a “miracle drug”, this perceived social integration 
can build fervor for cognitive enhancement. Scientific data on the effect of 
cognitive enhancers on healthy individuals is currently scarce as will be 
explained later. Enthusiasm for cognitive enhancement without sufficient data 
to support it may invite similar situations to those in the history of 
neuropharmacology where the important side effects were discovered following 
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widespread use. However, such unfortunate situations may also be prevented by 
learning from the examples of meprobamante, fluoxetine, and methylpenidate.  
What we have learned? 
One important lesson that the medical and ethics communities have 
learned from prior experience with neuropharmacology is the importance of 
foresight. The abuse potential of benziodiazepines was recognized by media 
reports and lay sources in the late 1960s. It was only in 1975 that some 
benzodiazepines became Schedule IV substances in the US [78]. In 1979, 
almost two decades after meprobamate treated America’s anxiety problems the 
US Senate intitiated its investigation on the “Use and Misuse of 
Benzodiazepines” [144]. In contrast to discussion about the effects of 
benzodiazepines, official inquiries into the ethical and social dimensions of 
cognitive enhancement have begun early. Governmental and academic 
institutions in the UK have spearheaded initiatives to examine the future of 
enhancing the cognition of healthy individuals. In 2005, the UK government 
launched The ForeSight Programme as a way to address future social and 
economic challenges with new technologies. Cognitive enhancement with 
neuropharmaceuticals was on the agenda for this project [67]. In 2007 the ethics 
department of the British Medical Association issued a report entitled Boosting 
your brainpower: ethical aspects of cognitive enhancement. In Québec, the 
Commission de l’éthique de la science et technologie (CEST) is studying recent 
increases in the use of neuropharmaceuticals and the ethics of their extended 
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use for enhancement. The CEST is interested in which values are involved in 
using neuropharmacology for enhancement, how to ensure informed consent 
and whether it is a public or private matter.2  The CEST’s report is slated for 
release at the beginning of 2009. The bulk of prevalence studies on the abuse of 
methylphenidate are recent dating from 2000. Now that some recent 
information about the phenomenon is available it is timely to move forward 
with further ethical analysis. These reports have begun to tackle this task and 
some topics need particular attention like the importance of social context, 
safety and efficacy, and commercial interests associated with cognitive 
enhancement of healthy individuals.  
Importance of social context 
When debating the merits and risks of a phenomenon like the non-
medical use of methylphenidate for cognitive enhancement, it is imperative to 
be aware of the social context in which it emerged. The rise of meprobamate to 
treat anxiety was linked to, “an era of unprecedented prosperity but also of 
uncertainty: suburban bomb shelters, duck-and-cover drills, expansion, a baby 
boom” [144]. Similarly, the rise of methylphenidate has been associated with a 
change in “societal pressures and public attitudes toward attention and behavior 
problems in children and adults” [46]. Ethical reflection upon cognitive 
enhancement should involve a concurrent awareness of its social context to 
better understand the nature of the phenomenon and make recommendations 
                                                 
2 http://www.ethique.gouv.qc.ca/Avis-sur-la-neuropharmacologie.html: December 4, 2008. 
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accordingly.  The importance of social awareness is illustrated by Kramer’s 
statement in his book Listening to Prozac: “The operational definition of 
wellness must be in relation to the demands an goals of society, here and now” 
[72].  Not only does social context first modulate the definition of health on the 
treatment-enhancement spectrum but it also affects other issues. For example, 
coercion of individuals to use cognitive enhancers is often cited as an issue in 
boiethics [51, 62, 86]. It was also identified as an important issue in the results 
of the discourse analysis presented in Chapter 5. However, the nature of 
coercion is vague without an indication of what causes this coercion and what 
stakeholders stand to gain. Both of these aspects are partly shaped by social 
context. Accordingly, before building a framework for cognitive enhancement, 
it is important that ethical discussion be guided by an awareness of its social 
context. However, this could pose a real challenge given the favorable opinions 
of influential bioethicists who emphasize the role of personal choice and 
individual rights in the choice to enhance cognition [59]. Gaining insights into 
the context of a non-medically approved and possibly socially sanctioned 
practice like cognitive enhancement will be challenging. 
Efficacy and safety 
The use of methylphenidate for cognitive enhancement as discussed in 
Chapter 5 raises important issues in terms of efficacy and safety which merit 
discussion in the broader debate on cognitive enhancement. Society’s 
relationship to technology has already been discussed. However, it is also 
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important to note that interest in new technologies arise from society’s 
assumption that they are valuable. Unfortunately, this “over-valuation” [115] 
may sometimes be independent of scientific evidence. To date, the benefits of 
cognitive enhancement for healthy individuals appear to be based on media 
reports and a few scientific studies. Furthermore, Lanni et al. argue that:   
From a pharmacology point of view the fact that a drug is 
clinically used to treat an attention disorder or a cognitive 
problem does not necessarily mean that a high level of the 
relevant molecule would produce a high performance in a 
normal individual [74].  
 
Before rallying behind cognitive enhancement and most definitely before any 
kind of regulation or approval is put forward, current scientific data must be 
assessed and interpreted carefully. 
There are few studies on the effects of cognitive enhancers on healthy 
individuals¸. It is important to describe in some detail the findings of these 
studies to capture how the results may be limited in their potential to be 
generalized and support favorable opinions toward the cognitive enhancement 
of healthy individuals. For example, Elliott et al.’s often-cited, double-blind, 
placebo-controlled study involved twenty-eight healthy male volunteers. 
Subjects were asked to perform a series of cognitive tasks focusing on spatial 
working memory and planning as well as attention and fluency. The results did 
show that methylphenidate improved performance on spatial working memory 
and planning but not on attention and fluency tasks. In addition, they showed 
that methylphenidate did not enhance performance tasks that had already been 
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learned [48]. The study conducted by Mehta et al. investigated changes in 
regional cerebral blood flow to also indicate that methylphenidate enhances 
spatial working memory. This study was on ten right-handed healthy male 
volunteers [87]. Barch et al. obtained results similar to Elliott et al. and Mehta 
et al. finding that amphetamine enhanced the spatial working memory of 
twenty-two healthy controls [13]. Contrarily to the three previous studies, Bray 
et al. reported that methylphenidate did not enhance the cognition of sleep-
deprived individuals. Ten young healthy males and ten young healthy females 
were asked to perform four cognitive tasks testing short-term memory, 
attention, motor speed and motor flexibility after a period of sleep-deprivation 
[21]. Farah et al. examined the effect of Adderall upon creativity, a component 
of cognition stimulants are suspected of stifling. In this double-blind, placebo-
controlled trial on sixteen young healthy volunteers they observed that the drug 
indeed enhanced creativity. However, the amount of enhancement depended 
upon the baseline performance of individuals: lower-performing individuals 
were more enhanced than high-performers [50]. These five studies indicate that 
stimulants have the potential to enhance certain elements of cognition but are 
not universal enhancers. The conflicting and fragmented results of these few 
studies provide very limited support for the enthusiastic portrayals of cognitive 
enhancement. 
The studies mentioned above are preliminary steps in terms of assessing 
the benefits of using neuropharmaceuticals for cognitive enhancement in 
healthy individuals but there are many points that need further clarification. 
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First, these studies need to be reproduced to confirm their results with uniform 
tasks to facilitate comparison and show robust beneficial effects. Second, the 
sample sizes must be larger and more diverse to generate data that could be 
generalized. Third, the sample populations must be more heterogeneous. Farah 
et al.’s study showed that the effect of a cognitive enhancer may vary indicating 
that there may be an “enhancement ceiling”. If this is the case, then this kind of 
technology may be less valuable than some expect because it would not be as 
powerful as originally thought. Also, variable efficacy would result in certain 
types of individuals being unable to enhance themselves thus perpetuating the 
debates on justice because of unequal access. Fourth, cognitive enhancement 
could become a long-term habit. For example, the survey on cognitive 
enhancement conducted by Nature revealed that respondents used cognitive 
enhancers on daily, weekly and monthly bases in almost even proportions [79]. 
Given potential chronic use of cognitive enhancers, their long-term effects must 
be assessed. Presently, for treatment with methylphenidate lasting more than 
four weeks, it is strongly recommended that the treating physician regularly 
reevaluate the prescription for methylphenidate [29]. Another question arising 
from long-term use is the abuse potential of methylphenidate. In the laboratory 
setting, methylphenidate has been shown to have an abuse potential [39, 71, 
147, 148]. Possibly the most interesting aspect of the data needed to support 
enhancement is how this kind of research can be ethically conducted on healthy 
individuals. Not only do researchers need to think of ways to prove the efficacy 
and safety of cognitive enhancers but they are also presented with the challenge 
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of doing it within current research ethics frameworks, namely in justifying 
potential risks and adverse effects in healthy individuals .  
Commercial interests 
 Cognitive enhancers for healthy people create a potentially lucrative 
market for holders of their patents.  Therefore commercial interests behind 
enhancement need to factor into discussions about its future. Our results show 
that commercialization of cognitive enhancement products was an important 
issue in the bioethics literature yet it is not emphasized in two of major reports 
to date (e.g., the British Medical Association and the UK ForeSight project). 
Given the profits that stand to be generated from expanded use of cognitive 
enhancers in healthy people, issues of commercialization should be addressed. 
This is particularly true given that public discourses can be shaped by such 
interests as described in Chapter 1. 
 The pharmaceutical industry will have a big stake in the cognitive 
enhancement of healthy individuals with pharmaceuticals and consequently it is 
important that research and marketing be managed transparently. Drug 
companies have previously received harsh criticism for allegedly exploiting the 
blurry line between treatment and enhancement in order to sell their products 
[30]. As discussed in Chapter 1, this allegation may be related to the growing 
market for lifestyle drugs where some lifestyle preferences are considered 
healthcare. It is unclear how this kind of marketing has influenced consumption 
of pharmaceuticals for enhancement thus far but it is likely to play an important 
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role in the future. Since cognitive enhancement as it is discussed in this thesis 
will involve healthy people, pharmaceutical companies may consider ways of 
responsibly researching and marketing cognitive enhancers.  
Two topics come to mind when reflecting upon transparency in the 
pharmaceutical industry. The first topic is relative to research. As with any 
pharmaceutical it is important to adequately elucidate the risks of taking the 
medication. The case of refecoxib (Vioxx) is a cautionary tale about the 
necessity of researching and reporting risks. In 2005 Adderall, a stimulant used 
to control the symptoms of AD/HD was pulled from the Canadian market, “due 
to safety information concerning the association of sudden deaths, heart-related 
deaths, and strokes in children and adults taking usual recommended doses of 
Adderall® and Adderall XR®” [27].  A report later recommended that the 
stimulant be put back on the market due to lack of evidence that Adderall posed 
more risk for sudden death than any other stimulant [76]. However, a study by 
Cheng et al. shows that the sudden withdrawal of Adderall caused concern 
among patients and their families [38]. This example does not mean to imply 
that Shire hid the cardiac risks of Adderall. Rather what it suggests is that given 
the elective nature of cognitive enhancement it is unclear why such risks be 
incurred by healthy individuals. Thus, pharmaceutical companies need to be 
certain that they can stand by claims of risk or lack thereof associated with 
marketed cognitive enhancers and this process needs to be honest and 
independent from commercial pressures.   
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In addition to risk, the benefits need to be realistically communicated 
and the complexity of this is well exemplified by the new generation of 
selective serotonin reuptake inhibitors used as antidepressants. An important 
and authoritative review by Kirsch et al. reported that out of thirty-five clinical 
trials for antidepressants examined, “overall effect of new generation 
antidepressant medications [was] below recommended criteria for clinical 
significance” [70]. Furthermore, the effect of the antidepressants was shown to 
vary depending upon the initial severity of the depression being treated. These 
findings suggest that antidepressants which are currently on the market may not 
be as efficacious as thought to be yet they are still being used in patients. 
Another study examined the publication of results from clinical trials on 
antidepressants registered with the US Food and Drug Administration (FDA) 
[145]. Turner et al. reported that out of seventy-four clinical trials registered 
with the FDA the results of 31% of the studies remained unpublished.  In 
conjunction to the recommendation made above about elucidating the efficacy 
of cognitive enhancers on healthy people, the data resulting from this research 
needs to first be divulged regardless of the results being positive or negative. 
Whichever the case, the results also need to be divulged realistically to avoid 
overstating efficacy and understating risks. Such issues in reporting the results 
of clinical trials might be taken into consideration when marketing cognitive 
enhancement products to give a fair and honest depiction of benefits. 
Responsible marketing is an important topic in the commercialization of 
pharmaceuticals. Marketing of pharmaceuticals sometimes “widens the 
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boundaries of illness [and] grows the markets for those who sell and deliver 
treatments” [93]. Some have called such creation of new medical conditions 
“disease mongering” [93]. One example of a condition that was allegedly 
mongered is that of social phobia. The antidepressant paroxetine (Paxil) 
obtained FDA approval after it was used off-label to treat this disorder. 
However, critics were skeptical about the way a normally shy person may be 
diagnosed with social phobia now that there seemed to be a biological treatment 
for it [14].  Another example of alleged disease mongering is restless leg 
syndrome. Originally a dopamine agonist used in the treatment of Parkinson’s 
disease, ropinirole (Requip) was found to be effective in calming an impairing 
urge to move one’s legs [158]. Again, it is difficult to determine whether an 
individual who feels the urge to move their legs has restless leg syndrome or is 
jittery. Whether cognitive enhancement of healthy individuals will be 
considered a part of health or sickness is still unclear. Ultimately, access to 
cognitive enhancement would likely alter what is considered to be health and 
wellness. In the future, should enhancers be available to consumers, the need 
for cognitive enhancement would have to be carefully framed and 
communicated in order to fit the definition of health of the time. 
Proper description of the benefits of cognitive enhancers is essential if 
they are to be available to the public. Markets for lifestyle drugs are growing. 
Some of the pharmaceuticals used for enhancement such as methylphenidate 
are only available through prescription. However, the public is increasingly 
exposed to drugs with enhancing properties. One route of this exposure is 
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direct-to-consumer advertising (DTCA). DTCA of prescription drugs has been 
linked to more requests for advertised pharmaceuticals and more prescriptions 
[91]. Currently, DTCA of prescription drugs is prohibited in Canada but 
permitted in New Zealand and the United States [90]. Therefore if cognitive 
enhancers are only available through physicians Canadians may be somewhat 
less exposed to the effect of DTCA. However, they are not likely to be shielded 
from DTCA present on the Internet or during radio and television broadcasts 
originating from countries where DTCA is permitted. There is a significant 
amount of neuroproducts marketed online ranging from neuroimaging services 
to neuropharmacology [113]. Research indicates stimulants are available online 
without a prescription [126]. For example, a recent Google search simply using 
the term “buy Ritalin online” yielded 407,000 hits. Out of the first one hundred 
hits, sixty of them were to online pharmacies selling the stimulant. The results 
in Chapter 5 show that some university students who use methylphenidate 
obtain it from online pharmacies. Racine et al. identified some important issues 
associated with obtaining neuroproducts over the Internet. First, gaps in 
regulations “leave the DTCA field open to questionable practices” such as the 
presentations of enthusiastic testimonials combined with the overstatement of 
health-related effects of natural neuroproducts which have not been 
scientifically tested and possibly the understatement of risks and insufficient 
information about contraindications [113]. Second, neuroproducts bought over 
the Internet bypass healthcare providers and consumers may therefore be 
lacking information as well as medical supervision. Last, there is a concern for 
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neurological and psychiatric patients which may also be extended to people 
seeking enhancement.  These populations may be vulnerable in a venue where 
they have the opportunity to self-diagnose and self-medicate without medical 
supervision. In the future the Internet could play a larger role in the marketing 
and selling of cognitive enhancers emphasizing the need to properly research 
and realistically represent their effects to the public. 
A potential role for public health 
 Many ethical and social issues are associated with the non-medical use 
of neuropharmaceuticals for cognitive enhancement of healthy individuals but it 
is unclear whether this phenomenon is currently a matter of public health or 
not. The 2007 report on enhancement from the British Medical Association 
discussed whether a role for public health was timely but did not conclude on 
the subject. Results of Chapter 5 showed that the relevance of public health 
interventions in the future of the cognitive enhancement of healthy people is a 
matter of perspective (and semantics). The lifestyle and enhancement 
paradigms, which focus on the benefits of cognitive enhancement, would most 
likely not consider cognitive enhancement a matter of public health but an 
individual’s prerogative. On the other hand, the prescription drug abuse 
paradigm which compares the non-medical use of methylphenidate for 
cognitive enhancement to a form of illicit drug abuse might suggest public 
health action. A closer look at cognitive enhancement practices with 
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methylphenidate (and other neuropharmaceuticals) may reveal the need for 
public health interventions.   
The prescription abuse paradigm considers the non-medical use of 
methylphenidate for cognitive enhancement to be happening outside of the 
confines of medicine. Several aspects of Health Canada’s definition of 
prescription abuse are present in the way methylphenidate is used for cognitive 
enhancement. For example, the non-medical use of methylphenidate is 
associated to the increased risk for harm, obtaining drugs from illegitimate 
sources, risky patters of use, deviation from medical practice and non-
therapeutic use [28]. With regard to cognitive enhancement with 
methylphenidate, the major concern is the last aspect of the definition, the non-
therapeutic use of a drug and how it leads to the other elements like obtaining 
the drug from illegitimate sources and risky patterns of use. Consequently, 
doctors are potentially being eased out of their role as “gatekeepers” to these 
types of drugs as suggested by Chatterjee [35]. Unfortunately, it is not well-
known if all healthcare providers are aware of the prevalence of the non-
medical use of methylphenidate and other neuropharmaceuticals for 
enhancement or if they would feel concerned at all. A survey of general 
practitioners on the subject of enhancement with pharmaceuticals in the 
Scandinavian Journal of Public Health indicated they may not. Bergstrom and 
Lynöe showed that general practitioners were not open to the use of 
prescriptions for enhancement purposes [18]. This position is reflected by only 
17.6% of general practitioners being in favor of enhancing concentration of 
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healthy individuals as opposed to 32.7% approval in the general public. General 
practitioners were more willing to improve mood (22.8%) but less willing to 
improve memory (8.7%). However, both general practitioners and the general 
public are unwilling to have society fund the use of pharmaceuticals for the 
enhancement of healthy individuals.  These results reflect that healthcare 
providers may generally not be aware of the prevalence of the non-medical use 
of pharmaceuticals for enhancement and that they potentially perceive 
enhancement to be outside the boundaries of medicine.  As discussed in 
Chapter 1, the medical field may consider cognitive enhancement to be outside 
of the realm of healthcare yet some aspects of the phenomenon may call for 
public health interventions. This creates puzzling situation where healthcare 
providers’ view of cognitive enhancement as a non-medical practice curtail a 
fuller analysis of its public health implications.  
Mainstream healthcare may be more involved in the cognitive 
enhancement of individuals than it appears at first glance or that is openly 
acknowledged. Chapter 5 presented evidence that methylphenidate was 
obtained using a host of methods. Some, like trafficking among students, black 
markets, Internet pharmacies and theft may not directly involve the healthcare 
system. However, there were also reports of students feigning symptoms of 
AD/HD in order to obtain legitimate prescriptions. Healthcare providers could 
therefore be involved in the phenomenon without knowing it because students 
could seek cognitive enhancement under the auspices of feigned mental illness. 
Further, the British Medical Association’s report on cognitive enhancement 
130 
 
recognizes that “Modern-day healthcare also includes some interventions where 
the aim is more explicitly to improve aspects of quality-of-life” citing examples 
such as oral contraception, and hair-loss treatments [22]. However, even when 
the pills are obtained on the black market they still, most likely, were paid for 
by a patient’s health insurance. Consequently, the use of medical personnel and 
financial resources for cognitive enhancement of healthy individuals could be 
putting a strain on healthcare systems. Viewed in this light, users of cognitive 
enhancers may actually be inviting public health action by slowly grafting their 
needs to medicine by using medical resources and expanding the goals of 
medicine.  
The last point to consider about the role of public health in cognitive 
enhancement has more to do with the “public” aspect of public health. Though 
the decision to use a cognitive enhancer may be up to the individual, the effects 
of the enhancement loom much larger. The choices of individuals may be 
impacting collective practice which makes the subject of cognitive 
enhancement a public matter. In Chapter 5, one of the important ethical issues 
evoked in all discourses was the changing of social practices and institutions 
due to cognitive enhancement.  The non-medical use of methylphenidate for 
cognitive enhancement by healthy individuals has been perceived to be 
promoting competition and favoring of quick fixes to enhance performance. If 
social practices are indeed tending toward valuing cognitive enhancement, 
important issues of autonomy and coercion may come to the forefront. 
Discussions about cognitive enhancement in the workplace have begun [4, 
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151]. Unlike previous public health efforts like the reduction of smoking and 
obesity, the social changes brought forward by cognitive enhancement could be 
difficult to modify since they reside mainly in the mood and behaviors of 
individuals.   
Public health action for the prevention of the non-medical use of 
pharmaceuticals for cognitive enhancement faces some important challenges. It 
is important that healthcare professionals become more aware of the non-
medical use of pharmaceuticals for cognitive enhancement. However, data from 
the US National Institutes of Health shows that over 40% of physicians have 
difficulty addressing the subject of prescription abuse with their patients. For 
physicians, the subject of prescription abuse appears to be even more difficult 
to tackle than stigmatized conditions like depression and alcoholism [94]. The 
burden of responsible management of prescriptions may well fall on healthcare 
professionals and patients alike but the reality is that  physicians have little or 
no control over what is done with prescriptions when patients leave their 
offices. The Ministère de la Santé et des Services Sociaux has been promoting 
the proper use of medications in Québec with its campaign “Using Medication: 
If and as required!”.3 The concern, of course, is whether any amount of 
education on the harms of prescription abuse for lifestyle purposes can trump 
social pressures to perform at the root of the need for enhancement. Lastly, in 
raising awareness among the public with regard to cognitive enhancement 
                                                 
3 http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2004/04-999-43a.pdf 
Access date: December 7, 2008. 
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public health faces a possible conflict of values. On one hand, public health 
action aims to prevent practices that are potentially harmful to the public’s 
health like taking a pharmaceutical without a prescription. On the other hand, 
raising awareness may inadvertently promote forms of cognitive enhancement 
of healthy individuals. Public health interventions will need to carefully 
consider whether they will decide to play a role in cognitive enhancement. If 
they do they will be faced with the decision of which strategy would benefit the 
public in a context where the phenomenon of cognitive enhancement with 
neuropharmaceuticals progresses. 
Future of enhancement 
 This general discussion has outlined some topics that merit further 
reflection to help elucidate the future directions of ethical discussion of the 
cognitive enhancement of healthy individuals with neuropharmacology. So far 
the directions have included awareness of social context, further research into 
efficacy and safety of neuropharmaceuticals in healthy people, transparency in 
commercialization and a possible role for public health. It is unclear how 
further discussion of these points will impact actual practices. However, it 
would be unfortunate if scholarship resulting from meaningful ethical 
deliberation remained academic. As mentioned in the previous section there is a 
risk of promoting cognitive enhancement of healthy individuals by bringing the 
public’s attention to it. However, censoring information about cognitive 
enhancement may not be any more beneficial. On the contrary, making 
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information about the ethics of cognitive enhancement available to stakeholders 
may add new dimensions to current discourses. 
 There are various stakeholders that could positively contribute to the 
ethical deliberation on cognitive enhancement and several reasons why their 
input would be beneficial. The general public represents a large and diverse 
group but before tackling the general public as a large group, it can be broken 
up into stakeholders. For the phenomenon of the non-medical use of 
methylphenidate these stakeholders include (at least) university students, 
parents of university students, healthcare providers, professors and educators, 
researchers, the media, the pharmaceutical industry, community groups and 
policy makers. Hardly any research exists regarding stakeholder perspectives on 
cognitive enhancement, a phenomenon gaining considerable prevalence. 
Examining stakeholder discourses would add richness and depth to 
deliberations on cognitive enhancement notably the issues of social pressure 
and the acceptability of the phenomenon. Blakemore has argued that gathering 
stakeholder perspectives contributes to the “empowerment of people to 
participate in public discussion and debate about where science should go and 
how technology should be applied” [19]. In the wake of an aging population, 
cognitive enhancement of otherwise healthy individuals may be an important 
component for the “mental wealth” of future societies which includes “mental 
capital” and “mental well-being” [17]. In fact, the motivation behind the UK 
ForeSight project is to examine the mental capital, i.e., cognitive and emotional 
resources, as well as the mental well-being i.e., ability of an individual to 
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realize their potential while working productively and creatively, of the aging 
population. In Chapter 5, different discourses yielded various recommendations 
for ways to prevent the non-medical use of methylphenidate for cognitive 
enhancement. These recommendations involved the participation of many of 
the aforementioned stakeholder groups. For example, it was suggested that 
healthcare providers modify prescription practices, the public comply with 
prescriptions, students learn more effective study habits instead of using 
cognitive enhancers and policy makers introduce legislation to ban or legalize 
enhancers. Therefore, if policy makers are to implement some of these 
recommendations it may be suitable to start engaging the stakeholders that are 
involved in such approaches.  
 Strategies to prevent the further non-medical use of methylphenidate for 
cognitive enhancement were suggested. However, what is needed is broader 
public discussion before the implementation of these interventions to avoid 
ineffective, hasty or inadequate approaches. Several models for public 
engagement already exist and may provoke broader public discussion on 
cognitive enhancement. The UK is one of the countries at the avant-garde in 
engaging the public in science discussions. The UK government has done 
several surveys to assess the public’s general science knowledge and to develop 
broader public discussions. One government taskforce for the promotion of 
public engagement even made it mandatory for holders of public funds to 
involve the public in activities relative to their research. However, after a series 
of events like the spread of AIDS, outbreaks of mad cow disease and debates 
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over genetically modified foods the UK public became distrustful of science. A 
marketing pole done in 1996 showed that scientists were among the most 
mistrusted professions just above journalists and politicians. The survey also 
showed that the public was especially critical of scientists with commercial ties 
[19]. Another survey from 2000 showed that there has been a shift in attitude 
producing a “crisis of confidence in science among the public” but that this 
crisis has “produced a new mood for dialogue” [19]. The UK public now 
participates in events like SciBars, discussions held in bars or cafés lead by 
leading experts in scientific topics of interest.  A similar model is used by the 
Bar des Science in Québec4 and more recently the Canadian Institutes of Health 
Research (CIHR). The CIHR Café Scientifique sessions are held all over the 
country5.  Similar events have been organized by the Groupe de Recherche en 
Éthique Biomédicale (GREB) at the Université de Montréal namely a citizen’s 
conference on the genome6.  While venues like SciBars offer a good 
opportunity to instruct the public they are not necessarily being engaged during 
deliberative processes. 
 Public engagement is more than just informing the public. It is listening 
to public voices to make a difference. Racine et al. have proposed a model 
where inquiry and debate on a given scientific development is at the center of a 
multi-dimensional communication between the scientific community, 
                                                 
4 http://www.bardessciences.qc.ca/ Access date: December 15, 2008. 
5 http://www.cihr-irsc.gc.ca/e/34951.html Access date: December 8, 2008. 
6 http://www.bioethique.umontreal.ca/GREB_PROD/index_fichiers/Page480.htm : Access date: 
December 15, 2008. 
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humanities and social science, the media as well as the public and stakeholders 
[108]. With this model, knowledge about advances in neuroscience, or any 
other branch of science, does not end when it reaches the public. Instead, public 
perceptions and opinion are fed back up the chain of knowledge to instruct the 
scientific community about what the public has understood about its work. 
Possibly the most interesting aspect of this model is that not only is there 
dialogue between scientist and the public but across other groups involved. For 
example, the humanities and social sciences can weigh in on scientific question 
but they can also examine the media’s coverage of it and the public’s 
appreciation of the questions. The multi-directional aspect of this model makes 
it an interesting way to engage stakeholders in ethical discussion of a 
phenomenon like cognitive enhancement which impact many groups. 
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This model is one of the many models proposed to set the stage for 
more deliberative ways to engage the public in science discussions. There are a 
few concrete examples that can provide guidance on how multi-directional 
approaches could be implemented. For example the “Citizen Voices Forums” 
organized by the Philadelphia Inquirer is a model created by the National 
Issues Forums and the Kettering Foundation [143]. During these forums, 
citizens from different stakeholder groups assemble and form working groups. 
Each group generates its own set of recommendations for a range of policy 
options on a certain scientific issue. The process is a deliberation in opposition 
Figure 6-1: Racine et al.’s multi-dimensional model for communication in 
neuroscience 
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to a debate because no winner emerges from these forums. Instead, everyone 
involved participates and gains a better understanding of how other groups 
experience the scientific issue at hand. 
 The models for public engagement outlined above may be interesting 
options for public engagement on the subject of cognitive enhancement. More 
interaction between stakeholders may foster understanding of some of the 
topics mentioned earlier in this discussion. For example, students could express 
the social pressures they are facing which contribute to a perceived need for 
enhancement. Scientists and healthcare professionals could explain the current 
state of knowledge about the efficacy and safety of cognitive enhancers to 
populations who use them. Scientists and healthcare professionals can also join 
forces with the pharmaceutical industry to promote transparency. Dialogue 
between stakeholders could be complementary to public health actions. 
Enhanced communication between stakeholders may even impact media 
reporting on cognitive enhancement providing a richer and broader spectrum of 
perspectives. Broader public discussion and multidirectional communication 
approaches will not solve all issues. However, they hold the promise of 
extending current discussion beyond academia to ensure that democratic 
processes shape the future uses of neuroscience and neurotechnology. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
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 Discourses on the non-medical use of neuropharmaceuticals for the 
cognitive enhancement of healthy individuals are complex.  The extent of this 
complexity becomes clearer when looking at the number of ethical and social 
issues that are raised by this phenomenon. Such issues can have effects at an 
individual level when considering potential changes in personhood and 
autonomy. They can also have broader implications on social practices and 
institutions such as healthcare and education. Noticeable differences in 
discourses may create “ethics blind spots” when we could actually benefit from 
concerted deliberation of the ethics of cognitive enhancement. However, 
identifying divergence between discourses may be a first step in fostering this 
kind of deliberation. 
 It is important to note that the materials examined in this thesis reflect 
mainly a North American perspective of the non-medical use of 
neuropharmaceuticals for the cognitive enhancement of healthy individuals. 
Chapter 6 stressed the importance of social context in relation to a phenomenon 
like this one. While the results of this thesis are highly relevant locally, they 
may not be applicable per se at an international level where perspectives are 
likely to differ. Varying concepts of health, distinct patters of pharmaceutical 
use, and cultural and social underpinnings of ethics are some of the potential 
variables. Hence, further understanding of the emergence and importance of the 
non-medical use of neuropharmaceuticals for the cognitive enhancement of 
healthy individuals may become clearer when international contexts are better 
examined.  
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The results and general discussion of this thesis on the ethics and public  
understanding of the non-medical use of neuropharmaceuticals for cognitive 
enhancement have created a lengthy task list for the future of bioethics. Public 
understanding and public engagement were discussed extensively in Chapters 1 
and 6, respectively. Future research could be directed at assessing the public’s 
current understanding  of the non-medical use of neuropharmaceuticals for 
cognitive enhancement. Asking relevant questions like whether the public 
considers the non-medical use of neuropharmaceuticals as prescription abuse or 
a lifestyle choice or even whether they feel pressured to engage in performance 
enhancement may help resolve some of the ethical issues evoked in academic 
and lay discourses. Data from public understanding research would help 
determine what kind of public health action is appropriate in the wake of a 
phenomenon that is likely to gain prevalence in a context of increased pressures 
for performance.  
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Section 1: Description of non-medical use of MPH 
1.1. Definitions and synonyms for non-medical use of MPH 
 Formal definition of non-medical use of MPH: Explicit definition of “non-
medical use” or “cognitive enhancement” (e.g., “This term includes the use 
of drugs and other interventions to modify brain processes with the aim of 
enhancing memory, mood and attention in people who are not impaired by 
illness or disorder” (Hall, 2004)) 
 Lay descriptions of non-medical use of MPH: Implicit definition of the non-
medical use of MPH (e.g., “Her pal is fueled with "smart pills" that increase 
her concentration, focus, wakefulness and short-term memory” (Garreau, 
2006)) 
 Distinction between treatment and enhancement: Descriptions of  the 
treatment-enhancement distinction as being blurry or explicitly defining the 
two terms 
1.2. Uses of MPH 
 Medical use: MPH used as treatment for ADHD 
 Cognitive and academic performance enhancement use: MPH used as a 
study aid 
 Recreational use: MPH used for motives unrelated to ADHD or 
enhancement (e.g., partying, used with alcohol) 
1.3. Aims of cognitive enhancement: Statements explaining why an individual would 
enhancement their cognition (e.g., could include motive of increasing memory) 
1.4. Extent of non-medical use of MPH 
Accepted 
Frequent 
Neutral 
Questionable 
 
Rare 
1.5. Description of practices of non-medical use of MPH 
 When is MPH used non-medically 
 Who is using MPH non-medically 
 Where is MPH used non-medically 
 How MPH is procured for non-medical use 
 Black market 
 Buying pills from other students 
 Feigning symptoms of ADHD 
 Online pharmacies 
 Other (e.g., theft) 
1.6. Types of non-medical uses reported 
 Methylphenidate 
 Other neuropharmaceuticals (e.g., modafinil) 
 Non neuropharmaceuticals (e.g., caffeine, natural products) 
 Other (e.g., transcranial magnetic stimulantion) 
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Section 2: Workings and effects of MPH 
2.1. How MPH works: Statements on the causes of the physiological and 
psychological effects of methylphenidate or why it produces such effects (including 
its mechanism of action).   
2.2. Physiological effects of non-medical use of MPH 
 Physiological negative effects of non-medical use of MPH (e.g., heart 
palpitations, increase in blood pressure, and loss of sleep and appetite) 
 Physiological positive effects of non-medical use of MPH (e.g., prolonged 
wakefulness, increase in energy level, or lack of negative effects of other 
stimulants i.e. the diuretic effect of coffee.) 
2.3. Psychological effects of non-medical use of MPH 
 Psychological negative effects of non-medical use of MPH (e.g., depression 
with withdrawal, psychosis, aggression, anxiety, hallucinations and 
paranoia) 
 Psychological positive effects of non-medical use of MPH (e.g., increases in 
alertness, concentration, memory, and confidence) 
2.4. Unknown effects of non-medical use of MPH (e.g., unclear whether MPH 
actually has an effect on concentration) 
2.5. Information on ADHD 
 Nature of ADHD: Medical definition of ADHD (e.g., symptoms, causes) 
 Prevalence of ADHD (in children and adults) 
Section 3: Ethical, social and legal issues associated with non-medical use of MPH* 
3.1. Abuse: Statements on the misuse of MPH but different from the dependence 
upon the drug (e.g., “The administration says that methylpenidate carries a high 
potential for abuse” (Phillips, 2006)) 
3.2. Authenticity, identity, and personhood: Statements pertaining to the conservation 
or changing of an individual’s identity following enhancement (e.g., “if we 
substantially improve our overall cognitive functioning, we may also alter aspects of 
our identity that are fundamental to who we are” (Butcher, 2003))  
3.3. Autonomy, individual rights, and informed consent: Statements pertaining to an 
individual’s freedom to choose to enhancement themselves (e.g., “people may feel 
that they must do so in order to succeed or just to stay where they are in competitive 
endeavors” (Mehlman, 2004)) 
3.4. Cheating: Statements on the issue of whether or not cognitive enhancement by 
means of methylphenidate provides an unfair advantage  
3.5. Commercialization: Statements pertaining to the involvement of business in the 
non-medical use of MPH (e.g., “pharmaceutical companies stand to make substantial 
profits” (Chatterjee, 2004)) 
3.6. Illegality: Statements making mention of the illegality of non-medical use of 
MPH (e.g., “sicne the drugs is classified as a controlled substance, possessing or 
distributing it without a doctor’s prescription is a felony” (Reinkink, 2001)) 
3.7. Injustice, access, and equality: Statements about matters of justice, distribution 
and rights (e.g., “We tacitly accept wide disparities in modifiers of cognition, as 
demonstrated by the acceptance of inequities in education, nutrition, and shelter” 
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(Chatterjee, 2004)) 
3.8. Overprescription: Statements on the prescription habits of physicians for 
methylphenidate (e.g., “the fact that students are giving away supplies means that 
they didn,t need them in the first place, or at least in the dosages prescribed” 
(Phillips, 2006)) 
3.9. Regulation and governance:  Statements about how cognitive enhancers should 
be governed and who should be responsible for regulation of these substances. (e.g., 
“legislators and the public will need to decide whether current regulatory frameworks 
are adequate for the regulation of neurocognitive enhancement, or whether new laws 
must be written and new agencies commissioned” (Farah, 2004)) 
3.10. Reliability of scientific research: Statements about the current state of scientific 
research on the effects of MPH on healthy individuals  
3.11. Safety: Statements about the possible negative side-effects of pharmacological 
enhancement (can include mention of lack of long-term data)  
3.12. Social meaning: Statements highlighting the impact of cognitive enhancement 
with methylphenidate on social values and practices (e.g., “Moreover, there is 
evidence that age-associated cognitive deterioration begins around age 30. If so, then 
everyone beyond that age might be regarded as cognitively impaired” (Mehlman, 
2004)) 
3.13. Social integration and acceptability: Statements about the emergence of 
cognitive enhancement in society (e.g., “The view that cognitive enhancement drugs 
are bad because they are not customary or traditional also is not persuasive. Caffeine 
has been used for centuries” (Mehlman 2004)) 
Section 4: Prevention of non-medical use of MPH and related challenges 
4.1 Solutions: Description of the measures university administrations and law 
enforcement agencies are taking in order to prevent abuse from starting and 
spreading (e.g., awareness campaigns) 
4.2 Challenges: Challenges that prevention efforts may be faced with (e.g., difficulty 
in controlling black markets) 
 
  
 
